[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 967
1. Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I, Martin PM, Ouafik L, Figarella-Branger D: Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene; 2006 May 4;25(19):2818-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization.
  • Glioblastoma (GBM) is a highly malignant glioma, which has the propensity to infiltrate throughout the brain in contrast to pilocytic astrocytoma (PA) of the posterior fossa, which does not spread and can be cured by surgery.
  • We have used Suppression Subtractive Hybridization to define markers that better delineate the molecular basis of brain invasion and distinguish these tumor groups.
  • [MeSH-major] Astrocytoma / genetics. Gene Expression Profiling. Genes, Neoplasm / physiology. Glioblastoma / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Subtraction Technique

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314830.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


2. Tamura Y, Kuroiwa T, Kajimoto Y, Miki Y, Miyatake S, Tsuji M: Endoscopic identification and biopsy sampling of an intraventricular malignant glioma using a 5-aminolevulinic acid-induced protoporphyrin IX fluorescence imaging system. Technical note. J Neurosurg; 2007 Mar;106(3):507-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic identification and biopsy sampling of an intraventricular malignant glioma using a 5-aminolevulinic acid-induced protoporphyrin IX fluorescence imaging system. Technical note.
  • Several neurosurgical studies have provided descriptions of the utility of fluorescence-guided tumor resection using a microscope.
  • However, fluorescence-guided endoscopic detection of a deep-seated brain tumor has not yet been reported.
  • The authors report their experience with an endoscopic biopsy procedure for a malignant glioma within the third ventricle using a 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX fluorescence imaging system.
  • A 5-ALA-induced fluorescence image of an intraventricular tumor is barely visible with the typical fluorescence endoscopic system used in other clinical fields because the intensity of excitation light at wavelengths of 390 to 405 nm through a cut-off filter is too weak to delineate a brain tumor.
  • A 5-ALA-induced fluorescence endoscopy performed using this system allowed the intraventricular tumor to be clearly visualized as a red fluorescent lesion.
  • The results indicate that this endoscopic system is useful in detecting an intraventricular fluorescent tumor.
  • [MeSH-major] Astrocytoma / surgery. Biopsy / methods. Brain Neoplasms / surgery. Fluorescence. Neuroendoscopy / methods. Surgery, Computer-Assisted / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367078.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


3. Goswami C, Chatterjee U, Sen S, Chatterjee S, Sarkar S: Expression of cytokeratins in gliomas. Indian J Pathol Microbiol; 2007 Jul;50(3):478-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic carcinoma, which is a common malignant tumor seen in the central nervous system is often difficult to distinguish from glioblastoma multiforme.
  • A panel consisting of GFAP (usually positive for astrocytic tumors) and cytokeratin (usually positive for metastatic carcinomas) is most commonly used for this purpose.
  • Forty-five tumors were analysed, including 35 glial neoplasms and 10 metastatic carcinomas of which 7 of the 32 astrocytic neoplasms (22%) showed focal immunoreactivity with pancytokeratin.
  • So our conclusion was that co-expression of GFAP and CK is a fairly common phenomenon, especially in case of undifferentiated and high grade gliomas and this must be kept in mind while differentiating these cases from metastatic carcinoma, as CK positivity does not rule out the diagnosis of a glial neoplasm.
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Glial Fibrillary Acidic Protein / metabolism. Glioblastoma / diagnosis. Glioblastoma / metabolism. Humans. Immunohistochemistry. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883112.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 68238-35-7 / Keratins
  •  go-up   go-down


Advertisement
4. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol; 2009 Oct;118(4):469-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
  • Somatic mutations in the IDH1 gene encoding cytosolic NADP+-dependent isocitrate dehydrogenase have been shown in the majority of astrocytomas, oligodendrogliomas and oligoastrocytomas of WHO grades II and III.
  • Preliminary data suggest an importance of IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this mutation in their tumors.
  • We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177 anaplastic oligoastrocytomas WHO grade III.
  • We report on an inverse association of IDH1 and IDH2 mutations in these gliomas and a non-random distribution of the mutation types within the tumor entities.
  • IDH1 mutations of the R132C type are strongly associated with astrocytoma, while IDH2 mutations predominantly occur in oligodendroglial tumors.
  • In addition, patients with anaplastic glioma harboring IDH1 mutations were on average 6 years younger than those without these alterations.
  • [MeSH-minor] Adult. Age Factors. Brain / pathology. Cell Differentiation. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Mutation. Prognosis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554337.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  •  go-up   go-down


5. Lehnhardt FG, Bock C, Röhn G, Ernestus RI, Hoehn M: Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed; 2005 Oct;18(6):371-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-resolution proton magnetic resonance spectroscopy was performed on tissue specimens from 33 patients with astrocytic tumors (22 astrocytomas, 11 glioblastomas) and 13 patients with meningiomas.
  • Increased anaplasia, with respect to malignant transformation, resulting in a higher malignancy grade, was present in 11 recurrences of 22 astrocytoma patients.
  • Spectroscopic features of tumor types, as determined on samples of the primary occurrences, were in good agreement with previous studies.
  • Compared with the respective primary astrocytomas, characteristic features of glioblastomas were significantly increased concentrations of alanine (Ala) (p = 0.005), increased metabolite ratios of glycine (Gly)/total creatine (tCr) (p = 0.0001) and glutamate (Glu)/glutamine (Gln) (p = 0.004).
  • Meningiomas showed increased Ala (p = 0.02) and metabolite ratios [Gly, total choline (tCho), Ala] over tCr (p = 0.001) relative to astrocytomas, and N-acetylaspartate and myo-inositol were absent.
  • Metabolic changes of an evolving tumor were observed in recurrent astrocytomas: owing to their consecutive assessments, more indicators of malignant degeneration were detected in astrocytoma recurrences (e.g.
  • Gly, p = 0.029; tCho, p = 0.034; Glu, p = 0.015; tCho/tCr, p = 0.001) in contrast to the comparison of primary astrocytomas with primary glioblastomas.
  • The present investigation demonstrated a correlation of the tCho-signal with tumor progression.
  • Significantly elevated concentrations of Ala (p = 0.037) and Glu (p = 0.003) and metabolite ratio tCho/tCr (p = 0.005) were even found in recurrent low-grade astrocytomas with unchanged histopathological grading (n = 11).
  • This may be related to an early stage of malignant transformation, not yet detectable morphologically, and emphasizes the high sensitivity of 1H NMR spectroscopy in elucidating characteristics of brain tumor metabolism.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Magnetic Resonance Spectroscopy / methods. Meningioma / metabolism. Neoplasm Recurrence, Local / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 John Wiley & Sons, Ltd
  • (PMID = 15959923.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons
  •  go-up   go-down


6. Hunter SB, Varma V, Shehata B, Nolen JD, Cohen C, Olson JJ, Ou CY: Apolipoprotein D expression in primary brain tumors: analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem; 2005 Aug;53(8):963-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apolipoprotein D (apoD) expression has been shown to correlate both with cell cycle arrest and with prognosis in several types of malignancy, including central nervous system astrocytomas and medulloblastomas.
  • Sixteen poorly infiltrating WHO grade I glial neoplasms (i.e., pilocytic astrocytomas and gangliogliomas) showed an average 20-fold higher apoD expression level compared with the 20 diffusely infiltrating glial neoplasms (i.e., glioblastoma, anaplastic astrocytoma, oligodendrogliomas; p=0.00004).
  • Analyzed as individual tumor groups, poorly infiltrating grade I pilocytic astrocytomas and gangliogliomas differed significantly from each tumor type within the diffusely infiltrating higher-grade category (p<0.05 for each comparison) but not from each other (p>0.05).
  • Conversely, each individual tumor type within the diffusely infiltrating category differed significantly from both pilocytic astrocytomas and gangliogliomas (p<0.05) but did not vary from other infiltrating tumors (p>0.05).
  • Ependymomas, non-infiltrating grade II neoplasms, expressed levels of apoD similar to or lower than levels expressed by the diffusely infiltrating gliomas.
  • In addition, apoD expression was 5-fold higher in the slowly proliferating grade I glial neoplasms compared with non-proliferating normal brain tissue (p=0.01), suggesting that apoD expression is not simply an inverse measure of proliferation.
  • ApoD expression measured by quantitative RT-PCR may be useful in the differential diagnosis of primary brain tumors, particularly pilocytic astrocytomas and gangliogliomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16055749.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins; 0 / Apolipoproteins D; 0 / Fixatives; 0 / Ki-67 Antigen; 1HG84L3525 / Formaldehyde; 8002-74-2 / Paraffin
  •  go-up   go-down


7. Chumbalkar VC, Subhashini C, Dhople VM, Sundaram CS, Jagannadham MV, Kumar KN, Srinivas PN, Mythili R, Rao MK, Kulkarni MJ, Hegde S, Hegde AS, Samual C, Santosh V, Singh L, Sirdeshmukh R: Differential protein expression in human gliomas and molecular insights. Proteomics; 2005 Mar;5(4):1167-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most common of the primary intracranial tumors with astrocytomas constituting about 40%.
  • Using clinically and histologically assessed astrocytomas, we have studied their protein profiles using a two-dimensional gel electrophoresis-mass spectrometry approach and identified differentially expressed proteins which may be useful molecular indicators to understand these tumors.
  • Examination of the protein profiles of 27 astrocytoma samples of different grades revealed 72 distinct, differentially expressed proteins belonging to various functional groups such as cytoskeleton and intermediate filament proteins, heat shock proteins (HSPs), enzymes and regulatory proteins.
  • Based on the consistency of their differential expression, 29 distinct proteins could be short-listed and may have a role in the pathology of astrocytomas.
  • Some were found to be differentially expressed in both Grade III and IV astrocytomas while others were associated with a particular grade.
  • A notable observation was underexpression of Prohibitin, a potential tumor suppressor protein, Rho-GDP dissociation inhibitor, Rho-GDI, a regulator of Rho GTPases and HSPs as well as destabilization of glial fibrillary acidic protein, GFAP, major protein of the glial filaments, in Grade III malignant tumors.
  • [MeSH-major] Astrocytoma / metabolism. Electrophoresis, Gel, Two-Dimensional / methods. Gene Expression Regulation, Neoplastic. Glioma / metabolism. Proteomics / methods

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15759318.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Molecular Chaperones; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


8. Ramnarayan R, Dodd S, Das K, Heidecke V, Rainov NG: Overall survival in patients with malignant glioma may be significantly longer with tumors located in deep grey matter. J Neurol Sci; 2007 Sep 15;260(1-2):49-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overall survival in patients with malignant glioma may be significantly longer with tumors located in deep grey matter.
  • BACKGROUND: The aim of this study was to assess the correlation of overall survival with tumor location (lobar vs. deep grey matter) and with other clinical and imaging variables in a cohort of patients with high grade gliomas.
  • METHODS: Adult patients with newly diagnosed supratentorial WHO grade 3 and 4 gliomas were evaluated.
  • Radiological data included tumor side, site (deep vs. lobar) and size, extent of peritumoral edema, and presence of midline shift.
  • RESULTS: A total of 121 patients were investigated, 23 (19.0%) with WHO grade 3 and 98 (81.0%) with WHO grade 4 gliomas.
  • The univariate Cox regression model demonstrated statistical significance for the variables age, side, site and size of tumor, presence of extensive edema, and presence of mass effect (>1 cm).
  • In the multivariate Cox models, tumor grade, site and size showed statistical significance.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / radiography. Child. Disease Progression. Female. Great Britain / epidemiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / radiography. Nerve Fibers, Myelinated / pathology. Prognosis. Regression Analysis. Survival Rate / trends. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17475281.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


9. Buecher B, Baert-Desurmont S, Leborgne J, Humeau B, Olschwang S, Frébourg T: Duodenal adenocarcinoma and Mut Y human homologue-associated polyposis. Eur J Gastroenterol Hepatol; 2008 Oct;20(10):1024-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These observations emphasize the malignant potential of MAP-associated duodenal polyposis and the need to enroll these patients into an upper gastrointestinal surveillance programme.
  • Moreover, one of our patients was also diagnosed with a scapular chondrosarcoma, the other one with a high-grade astrocytoma.
  • [MeSH-minor] Adult. Astrocytoma / genetics. Bone Neoplasms / genetics. Brain Neoplasms / genetics. Chondrosarcoma / genetics. Female. Humans. Middle Aged. Scapula

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18787472.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


10. Mita R, Coles JE, Glubrecht DD, Sung R, Sun X, Godbout R: B-FABP-expressing radial glial cells: the malignant glioma cell of origin? Neoplasia; 2007 Sep;9(9):734-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-FABP-expressing radial glial cells: the malignant glioma cell of origin?
  • B-FABP is also expressed in astrocytoma tumors and in some malignant glioma cell lines.
  • To address the role of B-FABP in malignant glioma, we have studied the growth properties of clonal populations of malignant glioma cells modified for B-FABP expression.
  • Here, we demonstrate that expression of B-FABP in B-FABP-negative malignant glioma cells is accompanied by the appearance of radial glial-like properties, such as increased migration and extended bipolar cell processes, as well as reduced transformation.
  • Conversely, B-FABP depletion in B-FABP-positive malignant glioma cells results in decreased migration, reduction in cell processes, and a more transformed phenotype.
  • Moreover, expression of B-FABP in astrocytomas is associated with regions of tumor infiltration and recurrence.
  • Rather than being a direct manifestation of the tumorigenic process, we propose that the ability of high-grade astrocytoma cells to migrate long distances from the primary tumor reflects properties associated with their cell of origin.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Carrier Proteins / physiology. Glioblastoma / pathology. Neoplasm Proteins / physiology. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Cell Adhesion / physiology. Cell Differentiation / physiology. Cell Division / physiology. Cell Line, Tumor / ultrastructure. Cell Membrane / ultrastructure. Cell Movement / physiology. Cell Surface Extensions / ultrastructure. Humans. Neoplasm Invasiveness / pathology. Oligodeoxyribonucleotides, Antisense / pharmacology. RNA Interference. Recombinant Fusion Proteins / antagonists & inhibitors. Recombinant Fusion Proteins / physiology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6B):4145-9 [9428348.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1955-60 [15138477.001]
  • [Cites] Brain Pathol. 1999 Apr;9(2):241-5 [10219741.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17528-32 [15574494.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9 [15827123.001]
  • [Cites] Neoplasia. 2005 May;7(5):435-45 [15967096.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Annu Rev Biomed Eng. 2005;7:105-50 [16004568.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Epilepsia. 2005;46 Suppl 7:15-21 [16201991.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):862-72 [16229809.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Glia. 2006 Mar;53(4):345-51 [16288463.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E5 [16709036.001]
  • [Cites] Nature. 2006 May 25;441(7092):444-50 [16724056.001]
  • [Cites] Nat Neurosci. 2006 Jun;9(6):787-97 [16715082.001]
  • [Cites] J Neurooncol. 2007 Sep;84(3):245-8 [17415524.001]
  • [Cites] BMC Cancer. 2006;6:97 [16623952.001]
  • [Cites] Lipids. 1999 Dec;34(12):1297-304 [10652989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6242-4 [10841526.001]
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):27045-54 [10854433.001]
  • [Cites] Dev Biol. 2001 Jan 1;229(1):15-30 [11133151.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6851-5 [11156378.001]
  • [Cites] Nat Neurosci. 2001 Feb;4(2):143-50 [11175874.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2323-8 [11226238.001]
  • [Cites] Curr Opin Lipidol. 2001 Jun;12(3):267-74 [11353329.001]
  • [Cites] Hum Cell. 2001 Mar;14(1):59-75 [11436354.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):683-8 [11723374.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):660-6 [12079514.001]
  • [Cites] Cell Mol Life Sci. 2002 Jul;59(7):1096-116 [12222958.001]
  • [Cites] Oncogene. 2003 May 8;22(18):2739-49 [12743598.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Jul;44(7):3170-7 [12824268.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):590-7 [14519394.001]
  • [Cites] Chem Phys Lipids. 2003 Nov;126(1):1-27 [14580707.001]
  • [Cites] Trends Neurosci. 2003 Nov;26(11):590-6 [14585598.001]
  • [Cites] Acta Neurochir (Wien). 2003 Dec;145(12):1097-103; discussion 1103 [14663567.001]
  • [Cites] Prog Lipid Res. 2004 Sep;43(5):383-402 [15458813.001]
  • [Cites] Anat Embryol (Berl). 1979 Jun 5;156(2):115-52 [111580.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] J Neuropathol Exp Neurol. 1981 Jul;40(4):390-409 [7252524.001]
  • [Cites] Exp Cell Res. 1982 Jul;140(1):85-93 [7049714.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):747-60 [3126193.001]
  • [Cites] Lab Invest. 1993 Jun;68(6):663-75 [8515653.001]
  • [Cites] Neuron. 1994 Apr;12(4):895-908 [8161459.001]
  • [Cites] Development. 1994 Sep;120(9):2637-49 [7956838.001]
  • [Cites] Cell. 1996 Feb 9;84(3):359-69 [8608589.001]
  • [Cites] J Biol Chem. 1996 Oct 4;271(40):24711-9 [8798739.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Lab Invest. 1997 Feb;76(2):277-84 [9042164.001]
  • [Cites] Am J Transplant. 2004 Jan;4(1):15-21 [14678030.001]
  • [Cites] Acta Neuropathol. 2004 Mar;107(3):272-6 [14730455.001]
  • [Cites] Neuron. 2004 Mar 25;41(6):881-90 [15046721.001]
  • [Cites] Oncogene. 1998 Apr 16;16(15):1955-62 [9591779.001]
  • (PMID = 17898869.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / FABP7 protein, human; 0 / Neoplasm Proteins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Recombinant Fusion Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC1993858
  • [Keywords] NOTNLM ; Astrocytoma / brain fatty acid-binding protein / infiltration / migration / radial glia
  •  go-up   go-down


11. Rachinger W, Grau S, Holtmannspötter M, Herms J, Tonn JC, Kreth FW: Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only. J Neurol Neurosurg Psychiatry; 2009 Oct;80(10):1134-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological evaluation revealed pilocytic astrocytoma (n = 2), WHO grade II glioma (n = 14), malignant glioma (n = 12), metastasis (n = 7), lymphoma (n = 5), cavernoma (n = 1), inflammatory disease (n = 2) or no tumour/gliosis (n = 3).
  • Patients with low grade glioma and malignant glioma showed a 1 year survival rate of 75% and 25%, respectively; the 1 year survival rate for patients with lymphoma or metastasis was 30%.
  • In the subgroup with a verified brainstem glioma, negative predictors for length of survival were higher tumour grade (p = 0.002) and Karnofsky performance score < or =70 (p = 0.004).

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19520698.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Szeifert GT, Prasad D, Kamyrio T, Steiner M, Steiner LE: The role of the Gamma Knife in the management of cerebral astrocytomas. Prog Neurol Surg; 2007;20:150-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the Gamma Knife in the management of cerebral astrocytomas.
  • The aim of this study was to assess the role of Gamma Knife radiosurgery in the complex management of cerebral astrocytomas.
  • Out of a series with more than 1,000 brain tumor cases treated at the Lars Leksell Center for Gamma Knife Surgery, UVA, 74 astrocytomas were selected for the present review.
  • The tumor either disappeared or decreased in 60% of grade 1 astrocytomas (n = 15), and 71% tumor control was achieved in grade 2 astrocytomas (n = 17) following radiosurgery.
  • In the high-grade glioma group (grades 3 and 4; n = 42) median survival time was 14 (range 2-58) months, and 25% of the patients were alive at 5 years after the treatment.
  • The best results were presented by the subgroup wherein previous craniotomy and debulking of the tumor were followed by radiosurgery (n = 7) with a median survival period of 24 (range 2-53) months.
  • Results of the present analysis suggest that stereotactic radiosurgery represents an alternative or supplementary treatment modality to conventional surgery in small-volume low-grade astrocytomas especially in deep-seated critical locations.
  • There is also evidence for the beneficial effect of radiosurgery on the survival of patients with high-grade gliomas; however, the limitations of a focused irradiation technique on a malignant infiltrative process are obvious.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Brachytherapy. Humans. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317983.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


13. Su YW, Chang MC, Chiang MF, Hsieh RK: Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol; 2005 Feb;71(3):315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
  • In patients with recurrent malignant glioma, treatment-related myelodysplastic syndrome (t-MDS) and acute leukemia are rare adverse effects because the median survival after relapse is limited.
  • We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ).
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Leukemia / chemically induced. Myelodysplastic Syndromes / chemically induced. Neoplasm Recurrence, Local / drug therapy


14. Scheithauer BW, Erdogan S, Rodriguez FJ, Burger PC, Woodruff JM, Kros JM, Gokden M, Spinner RJ: Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases. Am J Surg Pathol; 2009 Mar;33(3):325-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases.
  • Malignant peripheral nerve sheath tumors (MPNSTs) arising from cranial nerves or their branches are very uncommon.
  • In addition, 1 tumor involved the optic chiasm (n=1).
  • Only 1 tumor arose in brain parenchyma of (frontal lobe).
  • Five tumors arose in patients who satisfied clinical criteria for neurofibromatosis type 1 (NF1).
  • One patient with a vestibular tumor and presumed NF2 had previously undergone resection of a contralateral vestibular cellular schwannoma.
  • One posterior fossa tumor was a malignant melanotic schwannoma.
  • Four patients had postirradiation malignant peripheral nerve sheath tumors, 2 having been treated for optic chiasm glioma, both being NF1 affected.
  • One patient was irradiated for hypothalamic pilocytic astrocytoma and another for cervical Hodgkin disease.
  • All tumors were histologically high grade (6 grade III and 10 grade IV).
  • Malignant cranial nerve sheath tumors are rare and are associated with the same poor prognosis as those of spinal nerves at other sites.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065105.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Tanaka S, Akimoto J, Kobayashi I, Oka H, Ujiie H: Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction. Oncol Rep; 2008 Jul;20(1):165-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
  • A new adjuvant therapy, individual adjuvant therapy (IAT), which is individualized according to the results of real-time reverse-transcription polymerase chain-reaction (RT-PCR) for O6-methylguanine-DNA methyltransferase (MGMT), was used to treat malignant gliomas.
  • Immediately after the operation, mRNA expression for drug-resistance genes was investigated in frozen samples of malignant gliomas from 55 patients (30 glioblastoma multiformes, 20 anaplastic astrocytomas and 5 anaplastic oligodendroglial tumors) by real-time quantitative RT-PCR with specific primers for MGMT.
  • The response rate was 40.9% for glioblastoma multiformes, 60.0% for anaplastic astrocytomas and 80.0% for anaplastic oligodendroglial tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575733.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


16. Machado CM, Ikemori RY, Zorzeto TQ, Nogueira AC, Barbosa SD, Savino W, Schenka AA, Vassallo J, Heinrich JK, Boetcher-Luiz F, Verinaud L: Characterization of cells recovered from the xenotransplanted NG97 human-derived glioma cell line subcultured in a long-term in vitro. BMC Cancer; 2008;8:291
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In order to elucidate tumoral progression and drug resistance, cultured cell lines are valuable tools applied on tumor related assays provided they are well established and characterized.
  • Our laboratory settled the NG97 cell line derived from a human astrocytoma grade III, which started to develop and express important phenotypical characteristics of an astrocytoma grade IV after injection in the flank of nude mice.
  • Astrocytomas are extremely aggressive malignancies of the Central Nervous System (CNS) and account for 46% of all primary malignant brain tumors.
  • Progression to worse prognosis occurs in 85% of the cases possibly due to changes in cell tumor microenvironment and through biological pathways that are still unclear.
  • These cells were subcultivated to evaluate the possible contribution of these undifferentiated characteristics to the malignant progression phenotype.
  • Our results emphasize important queries about astrocytomas tumor progression.
  • [MeSH-major] Astrocytoma / pathology
  • [MeSH-minor] Animals. Antigens, CD29 / biosynthesis. Cell Growth Processes / physiology. Cell Line, Tumor. Chromosome Aberrations. Flow Cytometry. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Transplantation, Heterologous. Vimentin / biosynthesis

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1992 Jul;201(1):1-7 [1612114.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Jun;34(6):455-62 [9661048.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5158-65 [8221651.001]
  • [Cites] Cell Mol Neurobiol. 2005 Aug;25(5):929-41 [16133944.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8274-9 [16912208.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(4):661-5 [17141551.001]
  • [Cites] Sci Am. 2007 May;296(5):52-9 [17500414.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8995-9000 [17517657.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):133-48 [17874037.001]
  • [Cites] Brain. 2007 Dec;130(Pt 12):3336-41 [17998256.001]
  • [Cites] Cell Mol Neurobiol. 2007 Nov;27(7):831-43 [17703357.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Melanoma Res. 2000 Dec;10(6):507-14 [11198471.001]
  • [Cites] Neurosci Lett. 2001 Feb 16;299(1-2):140-4 [11166957.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):147-57 [9763427.001]
  • [Cites] Front Biosci. 1999 Feb 15;4:D188-99 [9989953.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):387-94 [10433932.001]
  • [Cites] CA Cancer J Clin. 1999 May-Jun;49(3):145-58 [10445014.001]
  • [Cites] J Neurosurg. 1965 Apr;22:368-73 [14318113.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):557-64 [15687310.001]
  • [Cites] Proteomics. 2005 Mar;5(4):1167-77 [15759318.001]
  • [Cites] Tissue Eng. 2005 May-Jun;11(5-6):865-76 [15998226.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):203-12 [11716071.001]
  • [Cites] Cell Mol Neurobiol. 2001 Aug;21(4):421-8 [11775071.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6837-45 [12460896.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2581-91 [12735302.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3407-11 [12776191.001]
  • [Cites] Semin Cell Dev Biol. 2003 Jun;14(3):161-8 [12948350.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] J Neuropathol Exp Neurol. 1981 May;40(3):201-29 [6260907.001]
  • [Cites] J Neurosci Res. 1981;6(6):741-8 [7334533.001]
  • [Cites] Dev Biol. 1982 Jun;91(2):286-95 [7047260.001]
  • [Cites] Eur J Biochem. 1984 Feb 1;138(3):465-71 [6319134.001]
  • [Cites] Development. 1987 Nov;101(3):565-82 [2458899.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):515-9 [8113864.001]
  • [Cites] Blood. 1994 Jun 1;83(11):3245-54 [7514905.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jul 15;75(2):77-89 [8055485.001]
  • [Cites] Int J Dev Neurosci. 1995 Jun-Jul;13(3-4):213-40 [7572277.001]
  • [Cites] Int J Cancer. 1996 Jul 17;67(2):275-82 [8760599.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):755-64 [9161727.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3624-31 [8339269.001]
  • (PMID = 18840301.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin
  • [Other-IDs] NLM/ PMC2572634
  •  go-up   go-down


17. Watanabe T, Katayama Y, Ogino A, Ohta T, Yoshino A, Fukushima T: Preliminary individualized chemotherapy for malignant astrocytomas based on O6-methylguanine-deoxyribonucleic acid methyltransferase methylation analysis. Neurol Med Chir (Tokyo); 2006 Aug;46(8):387-93; discussion 393-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary individualized chemotherapy for malignant astrocytomas based on O6-methylguanine-deoxyribonucleic acid methyltransferase methylation analysis.
  • This study was a preliminary trial of individualized chemotherapy based on MGMT methylation status in a total of 20 patients with newly diagnosed malignant astrocytomas (9 anaplastic astrocytomas and 11 glioblastomas multiforme).
  • Objective response to the PAV therapy was noted in all three patients with measurable residual tumor (2 complete responses and 1 partial response).
  • Objective response to the CE therapy was seen in only one of seven patients with measurable residual tumor (1 partial response).
  • The PAV regimen is effective against MGMT-methylated malignant astrocytomas, but the CE regimen is not useful at the given dose and schedule in MGMT-unmethylated tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / genetics. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. DNA Methylation. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936459.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Nitrosourea Compounds; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


18. Ranza E, Bertolotti A, Facoetti A, Mariotti L, Pasi F, Ottolenghi A, Nano R: Influence of imatinib mesylate on radiosensitivity of astrocytoma cells. Anticancer Res; 2009 Nov;29(11):4575-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of imatinib mesylate on radiosensitivity of astrocytoma cells.
  • Moreover, it is under investigation for the therapy of several other malignant tumours since protein kinases are frequently mutated or otherwise deregulated in human malignancies and they serve as a target for differentiating between tumour cells and normal tissues.
  • The objective of this study was to determine whether gamma radiation could sensitize astrocytoma cell lines to the effects of imatinib in vitro.
  • For this purpose, T98G and MOG-G-UVW astrocytoma cells were treated with imatinib alone or in combination with gamma radiation.
  • [MeSH-major] Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Piperazines / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Benzamides. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. Combined Modality Therapy. Dose-Response Relationship, Drug. Gamma Rays. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Imatinib Mesylate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032406.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


19. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S: Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med; 2005 Dec;19(8):677-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The uptake of L-methyl-11C-methionine (MET) by gliomas is greater than that by intact tissue, making methionine very useful for evaluation of tumor extent.
  • Tumors included diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, ependymoma, oligodendroglioma, medulloblastoma, dysembryoplastic neuroepithelial tumor, choroid plexus papilloma, central neurocytoma, optic glioma, gliomatosis cerebri, pleomorphic xanthoastrocytoma, and ganglioglioma.
  • Tumor activity and degree of malignancy were evaluated using Ki-67LI (LI: labeling index) and Kaplan-Meier survival curves.
  • The correlations between methionine uptake and tumor proliferation (tumor versus contralateral gray matter ratio (T/N) and Ki-67LI) were determined for the group of all subjects.
  • The existence of significant correlations between T/N and Ki-67LI and between SUV and Ki-67LI was determined for astrocytic tumors.
  • Receiver operating characteristics (ROC) analysis of T/N and standardized uptake value (SUV) was performed for the group of astrocytic tumors.
  • Ki-67LI differed significantly between the high-grade group and low-grade group at T/N levels between 1.5 and 1.8 on analysis using tumor proliferative potential (p = 0.019-0.031).
  • The prognosis differed significantly between the high-grade and low-grade groups when T/N was in the range of 1.6-1.8 (p = 0.028-0.032).
  • CONCLUSIONS: When analysis was confined to cases of astrocytic tumor, a correlation was noted between methionine accumulation and Ki-67LI.
  • For the astrocytic tumors, T/N ratio seemed to be more useful as a diagnostic indicator than SUV.
  • The cut-off level of T/N ratio for distinction between high-grade and low-grade astrocytoma appears to lie between 1.5 and 1.6.


20. Pinker K, Noebauer-Huhmann IM, Stavrou I, Hoeftberger R, Szomolanyi P, Weber M, Stadlbauer A, Grabner G, Knosp E, Trattnig S: High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors. Neuroradiology; 2008 Jan;50(1):9-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: To demonstrate intratumoral susceptibility effects in malignant brain tumors and to assess visualization of susceptibility effects before and after administration of the paramagnetic contrast agent MultiHance (gadobenate dimeglumine; Bracco Imaging), an agent known to have high relaxivity, with respect to susceptibility effects, image quality, and reduction of scan time.
  • METHODS: Included in the study were 19 patients with malignant brain tumors who underwent high-resolution, susceptibility-weighted (SW) MR imaging at 3 T before and after administration of contrast agent.
  • [MeSH-minor] Adult. Aged. Astrocytoma / diagnosis. Brain / pathology. Efficiency. Ependymoma / diagnosis. Female. Glioblastoma / diagnosis. Humans. Male. Middle Aged. Oligodendroglioma / diagnosis. Plasmacytoma / diagnosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2006 Jul;24(1):41-51 [16755540.001]
  • [Cites] J Magn Reson Imaging. 2005 Oct;22(4):439-50 [16163700.001]
  • [Cites] Neuroradiology. 2001 May;43(5):364-9 [11396739.001]
  • [Cites] NMR Biomed. 2001 Nov-Dec;14(7-8):453-67 [11746938.001]
  • [Cites] Invest Radiol. 2003 Jul;38(7):409-14 [12821854.001]
  • [Cites] Invest Radiol. 1999 Jun;34(6):427-34 [10353036.001]
  • [Cites] MAGMA. 1998 Aug;6(1):62-9 [9794291.001]
  • [Cites] Invest Radiol. 2002 Mar;37(3):114-9 [11882790.001]
  • [Cites] Radiology. 1997 Feb;202(2):511-6 [9015082.001]
  • [Cites] Invest Radiol. 2006 Mar;41(3):249-55 [16481907.001]
  • [Cites] J Comput Assist Tomogr. 2000 Nov-Dec;24(6):949-57 [11105717.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):118-23 [10441013.001]
  • (PMID = 17876570.001).
  • [ISSN] 1432-1920
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 15G12L5X8K / gadobenic acid; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


21. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B: MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer; 2009 Jan;45(1):146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
  • AIMS: To investigate the correlation between O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and benefit from temozolomide in patients with recurrent high-grade glioma.
  • RESULTS: A subgroup of 38 patients who were chemotherapy-naive at recurrence was analysed (22 glioblastoma, 12 anaplastic astrocytoma [AA] and 4 anaplastic oligoastrocytoma [AOA]); none had 1p/19q loss.
  • By Cox multivariate analysis, tumour grade and MGMT promoter methylation correlated with time to progression (p<0.05); MGMT promoter methylation correlated with superior overall survival in AA/AOA but not in glioblastoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Methylation. Female. Glioblastoma / drug therapy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945611.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


22. Wang CC, Zhang JT, Liu AL: [Surgical management of brain-stem gliomas: a retrospective analysis of 311 cases]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb;27(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this series, total excision rate of the tumor was 40.5%, subtotal 29.9%, partial 29.6%, and operative mortality 1.3%.
  • Five years survival rate is 67% in ependymoma patients, 42% in astrocytoma patients.
  • For malignant ones, partial removal may prolong survival and facilitate the following combined therapy.
  • [MeSH-major] Astrocytoma / surgery. Brain Stem Neoplasms / surgery. Ependymoma / surgery. Glioblastoma / surgery. Neurosurgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782484.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M: Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res; 2005 Feb 1;11(3):1119-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
  • PURPOSE: Allelic loss at 1p is seen in 70% to 85% of oligodendrogliomas (typically in association with 19q allelic loss) and 20-30% of astrocytomas.
  • Because most 1p deletions in gliomas involve almost the entire chromosome arm, narrowing the region of the putative tumor suppressor gene has been difficult.
  • The latter group included both low-grade tumors (oligodendroglioma, diffuse astrocytoma, and "oligoastrocytoma") and high-grade tumors (anaplastic oligodendrogliomas, anaplastic astrocytomas, anaplastic oligoastrocytomas).
  • RESULTS: Allelic losses on 1p and 19q, either separately or combined, were more common in classic oligodendrogliomas than in either astrocytomas or oligoastrocytomas (P < 0.0001).
  • There was no significant difference in 1p/19q LOH status between low-grade and anaplastic oligodendrogliomas.
  • In contrast, no astrocytomas and only 6 of 30 (20%) oligoastrocytic tumors had combined 1p/19q loss.
  • Although rare, 1p deletions were more often segmental in astrocytomas (5 of 6, 83%) than in oligodendrogliomas (3 of 35, 9%; P = 0.006).
  • Eleven tumors (6 oligodendrogliomas or having oligodendroglial components, 5 purely astrocytic) with small segmental 1p losses underwent further detailed LOH mapping.
  • All informative tumors in the oligodendroglial group and 2 of 3 informative astrocytomas showed LOH at 1p36.23, with a 150-kb MDR located between D1S2694 and D1S2666, entirely within the CAMTA1 transcription factor gene.
  • [MeSH-minor] Adult. Astrocytoma / genetics. Astrocytoma / pathology. Calcium-Binding Proteins / genetics. Chromosome Deletion. Chromosome Mapping. Expressed Sequence Tags. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Microsatellite Repeats. Mutation. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709179.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CAMTA1 protein, human; 0 / Calcium-Binding Proteins; 0 / Trans-Activators
  •  go-up   go-down


24. Jeannin S, Lebrun C, Van Den Bos F, Olschwang S, Bourg V, Frenay M: [Turcot's syndrome confirmed by molecular biological tests]. Rev Neurol (Paris); 2006 Jun;162(6-7):741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Syndrome de Turcot confirmé par biologie moléculaire.
  • INTRODUCTION: Turcot's syndrome is characterized clinically by the concurrence of a primary brain tumor and a familial adenomatous polyposis or a hereditary nonpolyposis colorectal cancer.
  • OBSERVATION: We report a case of a 45-year-old woman who underwent in 1995 neuro-oncological treatment for an anaplastic astrocytoma (grade III according to the World Health Organization classification).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840983.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


25. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC: Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus; 2006;20(4):E1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rising trends were noticed for glioblastoma multiforme (GBM), oligodendroglioma, anaplastic astrocytoma, medulloblastoma, and mixed glioma, and falling trends were observed for astrocytoma not otherwise specified and malignant glioma.
  • [MeSH-major] Astrocytoma / epidemiology. Brain Neoplasms / epidemiology. Glioblastoma / epidemiology. Glioma / epidemiology. Medulloblastoma / epidemiology. Oligodendroglioma / epidemiology. Population Surveillance

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709014.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, Kelly PJ: Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery; 2006 Jun;58(6):1099-107; discussion 1099-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.
  • OBJECTIVE: To determine whether relative cerebral blood volume (rCBV) can predict patient outcome, specifically tumor progression, in low-grade gliomas (LGGs) and thus provide a second reference standard in the surgical and postsurgical management of LGGs.
  • METHODS: Thirty-five patients with histologically diagnosed LGGs (21 low-grade astrocytomas and 14 low-grade oligodendrogliomas and low-grade mixed oligoastrocytomas) were studied with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
  • Tumor volumes and CBV measurements were obtained at the initial examination and again at follow-up to determine the association of rCBV with tumor volume progression.
  • Lesions with low baseline rCBV (< 1.75) demonstrated stable tumor volumes when followed up over time, and lesions with high baseline rCBV (> 1.75) demonstrated progressively increasing tumor volumes over time.
  • CONCLUSION: Dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging may be used to identify LGGs that are either high-grade gliomas, misdiagnosed because of sampling error at pathological examination or that have undergone angiogenesis in the progression toward malignant transformation.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Magnetic Resonance Imaging. Oligodendroglioma / therapy


27. Kitai R, Horita R, Sato K, Yoshida K, Arishima H, Higashino Y, Hashimoto N, Takeuchi H, Kubota T, Kikuta K: Nestin expression in astrocytic tumors delineates tumor infiltration. Brain Tumor Pathol; 2010 Apr;27(1):17-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in astrocytic tumors delineates tumor infiltration.
  • Nestin is an intermediate filament protein expressed in undifferentiated cells during central nervous system development, and glioma is known to be a highly infiltrative tumor.
  • We determined whether nestin was expressed in astrocytic tumors and could identify infiltrating tumor cells.
  • We screened 65 archival, paraffin-embedded adult astrocytic tumors using immunohistochemical staining and computerized overlaid photographs.
  • The intensity of nestin expression corresponded to the tumor grade.
  • All 33 glioblastoma cases showed positive and extensive staining, which was less positive in diffuse astrocytoma.
  • Overlaid images showed that nestin immunostaining delineated tumor invasion into adjacent gray and white matter.
  • Nestin is a useful marker for examining the infiltration of malignant cells into surrounding tissue.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Intermediate Filament Proteins / metabolism. Intermediate Filament Proteins / physiology. Nerve Tissue Proteins / metabolism. Nerve Tissue Proteins / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Child. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Nestin. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425043.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


28. Malakootian M, Mowla SJ, Saberi H, Asadi MH, Atlasi Y, Shafaroudi AM: Differential expression of nucleostemin, a stem cell marker, and its variants in different types of brain tumors. Mol Carcinog; 2010 Sep;49(9):818-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total RNA was extracted from 59 brain tumor samples, and the expression of different NS spliced variants was measured by semi-quantitative RT-PCR.
  • Furthermore, to decipher the potential involvement of NS in brain tumorogenesis, its expression was knocked-down by means of RNA interference (RNAi) in two malignant glioma (U-87MG and A172), one astrocytoma (1321N1) and one medulloblastoma (DAOY) cell lines.
  • Among the NS spliced variants, variant "1" and variant "3" were detected in the majority of tumor samples, whereas variant "2" was only detectable in few samples.
  • Moreover, the intensity of the expression was correlated with the grade of the tumors (P < 0.05).
  • As expected, a nucleolar/nucleoplasmic localization of NS protein was observed in the examined tumor samples.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Glioma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20572164.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins; 0 / RNA, Small Interfering
  •  go-up   go-down


29. Jung TY, Jung S, Ryu HH, Jeong YI, Jin YH, Jin SG, Kim IY, Kang SS, Kim HS: Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg; 2008 Aug;109(2):273-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results were validated by reverse transcription polymerase chain reaction and Northern blot analysis to detect possible genetic changes as the determining factors for the motility of the malignant glioma.
  • On immunohistochemical staining, galectin-1 expression was increased in higher-grade glioma subgroups (p = 0.027).
  • CONCLUSIONS: Diffuse gliomas demonstrated higher expression levels than pilocytic astrocytoma in the Western blot.
  • Galectin-1 appears to modulate migration and invasion in human glioma cell lines and may play a role in tumor progression and invasiveness in human gliomas.
  • [MeSH-minor] Astrocytoma / metabolism. Astrocytoma / pathology. Astrocytoma / physiopathology. Blotting, Northern. Blotting, Western. Cell Division / physiology. Cell Line, Tumor. Cell Movement / physiology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Invasiveness. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18671640.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Galectin 1; 0 / LGALS1 protein, human
  •  go-up   go-down


30. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol; 2006 May;111(5):483-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.
  • Podoplanin is putatively involved in cancer cell migration, invasion, metastasis, and malignant progression and may be involved in platelet aggregation.
  • However, little information exists about its role in CNS astrocytic tumors.
  • In this study, 188 astrocytic tumors (30 diffuse astrocytomas, 43 anaplastic astrocytomas, and 115 glioblastomas) were investigated using immunohistochemistry with an anti-podoplanin antibody, YM-1.
  • In 11 of 43 anaplastic astrocytomas (25.6%) and in 54 of 115 glioblastomas (47.0%), podoplanin was expressed on the surface of anaplastic astrocytoma cells and glioblastoma cells, especially around necrotic areas and proliferating endothelial cells.
  • On the other hand, podoplanin expression was not observed in diffuse astrocytoma (0/30: 0%).
  • Furthermore, we investigated the expression of podoplanin using quantitative real-time PCR and Western blot analysis in 54 frozen astrocytic tumors (6 diffuse astrocytomas, 14 anaplastic astrocytomas, and 34 glioblastomas).
  • Podoplanin mRNA and protein expression were markedly higher in glioblastomas than in anaplastic astrocytomas.
  • These data suggest that podoplanin expression might be associated with malignancy of astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Central Nervous System Neoplasms / metabolism. Glioblastoma / metabolism. Membrane Glycoproteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Blotting, Western. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596424.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / PDPN protein, human; 0 / RNA, Messenger
  •  go-up   go-down


31. Skardelly M, Armbruster FP, Meixensberger J, Hilbig H: Expression of Zonulin, c-kit, and Glial Fibrillary Acidic Protein in Human Gliomas. Transl Oncol; 2009 Aug 18;2(3):117-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hallmarks of human malignant gliomas are their marked invasiveness and vascularity.
  • Because angiogenesis and tumor invasion have been associated with extracellular matrix degradation and intercellular tight junctions, the involvement of zonulin in glioma biology is in the focus.
  • We selected for histological examination five cases of glioblastoma WHO IV (nomenclature of the World Health Organization) and one case each from astrocytoma WHO III, meningioma WHO III, and meningioma WHO I as control samples.
  • The meningioma WHO I is regarded as benign, whereas the meningioma WHO III is recognized as the transition form of malignant tumors in humans.
  • In differently graded tumors, we found differently graded involvement of blood vessels in the tumor development, explaining patients' survival.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2006 Apr;41(4):408-19 [16635908.001]
  • [Cites] Clin Neuropathol. 2006 May-Jun;25(3):107-14 [16719406.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):105-9 [16205964.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):163-7 [16132509.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):195-202 [16132504.001]
  • [Cites] J Clin Invest. 1989 Feb;83(2):724-7 [2492310.001]
  • [Cites] J Clin Invest. 1989 Apr;83(4):1089-94 [2649511.001]
  • [Cites] Infect Immun. 2003 Apr;71(4):1897-902 [12654806.001]
  • [Cites] Gut. 2003 Feb;52(2):218-23 [12524403.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1607-15 [12404235.001]
  • [Cites] Ann N Y Acad Sci. 2000;915:214-22 [11193578.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19160-5 [11278543.001]
  • [Cites] J Cell Sci. 2000 Dec;113 Pt 24:4435-40 [11082037.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Nov;24(6):687-91 [19122516.001]
  • [Cites] J Pathol. 2007 Mar;211(4):481-8 [17294421.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • (PMID = 19701495.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2730142
  •  go-up   go-down


32. Marie SK, Okamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, Cohen T, Camargo AA, Kosoy A, Carlotti CG Jr, Toledo S, Moreira-Filho CA, Zago MA, Simpson AJ, Caballero OL: Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer; 2008 Feb 15;122(4):807-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas.
  • We have performed cDNA microarray analyses to identify gene expression differences between highly invasive glioblastoma multiforme (GBM) and typically benign pilocytic astrocytomas (PA).
  • Despite the significant clinical and pathological differences between the 2 tumor types, only 63 genes were found to exhibit 2-fold or greater overexpression in GBM as compared to PA.
  • In the examination of more than 100 tumors of the central nervous system, we found progressively higher expression of MELK with astrocytoma grade and a noteworthy uniformity of high level expression in GBM.
  • We found neither gene promoter hypomethylation nor amplification to be a factor in MELK expression, but were able to demonstrate that MELK knockdown in malignant astrocytoma cell lines caused a reduction in proliferation and anchorage-independent growth in in vitro assays.
  • Among them, MELK correlated with malignancy grade in astrocytomas and represents a therapeutic target for the management of the most frequent brain tumors in adult and children.
  • [MeSH-major] Astrocytoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Glioblastoma / genetics. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Adult. Apoptosis. Brain / metabolism. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Cell Proliferation. Child. DNA Methylation. Gene Dosage. Humans. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17960622.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 2.7.1.- / MELK protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


33. Tuominen H, Lohi J, Maiche A, Törmänen J, Baumann P: Mediastinal metastasis of glioblastoma multiforme evolving from anaplastic astrocytoma. J Neurooncol; 2005 Nov;75(2):225-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal metastasis of glioblastoma multiforme evolving from anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / secondary
  • [MeSH-minor] Adult. Disease Progression. Fatal Outcome. Follow-Up Studies. Gene Deletion. Genes, p16. Glial Fibrillary Acidic Protein / metabolism. Homozygote. Humans. Male. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Salvage Therapy. Survival Analysis. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1778-82 [4027909.001]
  • [Cites] Arch Anat Cytol Pathol. 1995;43(5-6):342-9 [8729851.001]
  • [Cites] J Neurosurg. 1971 May;34(5):697-701 [4326303.001]
  • [Cites] Digestion. 2000;61(3):219-22 [10773729.001]
  • [Cites] Lancet Oncol. 2002 Aug;3(8):498-507 [12147436.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] J Am Acad Dermatol. 2002 Feb;46(2):297-300 [11807444.001]
  • [Cites] J Neurosurg. 1969 Jul;31(1):50-8 [4307543.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):107-14 [11716064.001]
  • [Cites] J Neurosurg. 2000 Nov;93(5):887-90 [11059674.001]
  • (PMID = 16132499.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


34. Elsir T, Eriksson A, Orrego A, Lindström MS, Nistér M: Expression of PROX1 Is a common feature of high-grade malignant astrocytic gliomas. J Neuropathol Exp Neurol; 2010 Feb;69(2):129-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PROX1 Is a common feature of high-grade malignant astrocytic gliomas.
  • PROX1 is a prospero-related transcription factor that plays a critical role in the development of various organs including the mammalian lymphatic and central nervous systems; it controls cell proliferation and differentiation through different transcription pathwaysand has both oncogenic and tumor-suppressive functions.
  • We investigated PROX1 expression patterns in 56 human astrocytic gliomas of different grades using immunohistochemistry.
  • An average of 79% of cells in World Health Organization Grade IV (glioblastoma, n = 15) and 57% of cells in World Health Organization Grade III (anaplastic astrocytoma, n = 13) were strongly PROX1 positive; low-grade diffuse astrocytomas (Grade II, n = 13) had 21% of cells that were strongly positive; Grade I tumors (n = 15) had 1.5%; and non-neoplastic brain tissue (n = 15) had 3.7% of cells that were PROX1 positive.
  • Analyses of coexpression with proliferation markers suggest that PROX1+ cells have a marginally lower rate of proliferation than other tumor cells but are still mitotically active.
  • We conclude that PROX1 may constitute a useful tool for the diagnosis and grading ofastrocytic gliomas and for distinguishing Grade III and Grade IV tumors from Grade I and Grade II tumors.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Homeodomain Proteins / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084020.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Biomarkers; 0 / Homeodomain Proteins; 0 / MAP2 protein, human; 0 / Microtubule-Associated Proteins; 0 / Nerve Tissue Proteins; 0 / Tubulin; 0 / Tumor Suppressor Proteins; 0 / neuronal nuclear antigen NeuN, human; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


35. Chamberlain MC, Johnston S: Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol; 2009 Feb;91(3):359-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
  • A retrospective study of bevacizumab only in adults with recurrent temozolomide (TMZ)-refractory anaplastic astrocytoma (AA) with a primary objective of determining progression free survival (PFS).
  • Bevacizumab-related toxicity included fatigue (14 patients; 2 grade 3), leukopenia (7; 1 grade 3), deep vein thrombosis (5; 2 grade 3), hypertension (5; 1 grade 3), anemia (4; 0 grade 3) and wound dehiscence (1; 1 grade 3).
  • Time to tumor progression ranged from 1 to 20 months (median: 7).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1981 Nov;55(5):749-56 [7310496.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1379-85 [1325539.001]
  • [Cites] Ann Neurol. 2003 Oct;54(4):479-87 [14520660.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):253-8 [15279718.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1592-6 [9389920.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):89-95 [17327573.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Stat Med. 1991 May;10(5):749-55 [2068428.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Surg Neurol. 1993 Jun;39(6):538-43 [8390727.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):601-8 [17432710.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):459-63 [3546620.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] J Neurosurg. 1990 Apr;72 (4):583-8 [2319317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):601-6 [1651302.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):3-8 [1572829.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):593-7 [1429080.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1213-20 [15022289.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1485-91 [12697871.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • (PMID = 18953491.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


36. MacDonald TJ, Pollack IF, Okada H, Bhattacharya S, Lyons-Weiler J: Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol; 2007;377:203-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis.
  • Astrocytoma is graded as pilocytic (WHO grade I), diffuse (WHO grade II), anaplastic (WHO grade III), and glioblastoma multiforme (WHO grade IV).
  • The progression from low- to high-grade astrocytoma is associated with distinct molecular changes that vary with patient age, yet the prognosis of high-grade tumors in children and adults is equally dismal.
  • Whether specific gene expression changes are consistently associated with all high-grade astrocytomas, independent of patient age, is not known.
  • To address this question, we reanalyzed the microarray datasets comprising astrocytomas from children and adults, respectively.
  • We identified nine genes consistently dysregulated in high-grade tumors, using four novel tests for identifying differentially expressed genes.
  • Four genes encoding ribosomal proteins (RPS2, RPS8, RPS18, RPL37A) were upregulated, and five genes (APOD, SORL1, SPOCK2, PRSS11, ID3) were downregulated in high-grade by all tests.
  • Expression results were validated using a third astrocytoma dataset.
  • APOD, the most differentially expressed gene, has been shown to inhibit tumor cell and vascular smooth muscle cell proliferation.
  • This suggests that dysregulation of APOD may be critical for malignant astrocytoma formation, and thus a possible novel universal target for therapeutic intervention.
  • Further investigation is needed to evaluate the role of APOD, as well as the other genes identified, in malignant astrocytoma development.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Gene Expression. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Adult. Child. Chromosomes, Human. Cluster Analysis. Data Interpretation, Statistical. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Models, Genetic. Neoplasm Recurrence, Local. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634619.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 49
  •  go-up   go-down


37. Learn CA, Grossi PM, Schmittling RJ, Xie W, Mitchell DA, Karikari I, Wei Z, Dressman H, Sampson JH: Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. J Neuroimmunol; 2007 Jan;182(1-2):63-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the study of malignant glioma, we have previously characterized a highly tumorigenic murine astrocytoma, SMA-560, which arose spontaneously in an inbred, immunocompetent VM/Dk mouse.
  • Using this cell line as a model of murine glioma, we performed DNA microarray analysis of autologous normal murine astroctyes (NMA) and SMA-560 tumor cells grown in monolayer culture or intracranially in syngeneic immunocompetent or immunocompromised hosts in order to determine whether tumors grown in vitro recreate the complex genetic regulation that occurs in vivo.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimmunol. 1999 Oct 29;99(2):195-204 [10505975.001]
  • [Cites] J Neurovirol. 1998 Apr;4(2):148-58 [9584952.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9 [15827123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8287-92 [15928080.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5292-9 [16033848.001]
  • [Cites] Mol Ther. 2005 Oct;12(4):585-98 [16095972.001]
  • [Cites] Leuk Lymphoma. 2005 Dec;46(12):1689-98 [16263570.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Semin Cancer Biol. 2006 Feb;16(1):3-15 [16153857.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1391-6 [16263789.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3294-302 [16540683.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294-305 [16857805.001]
  • [Cites] Annu Rev Pathol. 2006;1:97-117 [18039109.001]
  • [Cites] J Neuroimmunol. 2000 Feb 1;103(1):16-25 [10674985.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7503-8 [10852962.001]
  • [Cites] Ann Neurol. 2002 Mar;51(3):393-405 [11891838.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):683-6 [12016138.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):251-66 [12118559.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3496-502 [12429640.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4831-8 [15269159.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3216-24 [15131063.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):37-42 [15015573.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5316-26 [15328167.001]
  • [Cites] Acta Neuropathol. 1980;51(1):53-64 [7435141.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4375-82 [7671250.001]
  • [Cites] Cytokine. 1995 Aug;7(6):580-8 [8580376.001]
  • [Cites] Neurosurgery. 1997 Dec;41(6):1365-72; discussion 1372-3 [9402588.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):302-9 [9443409.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):90-6 [15701286.001]
  • (PMID = 17137636.001).
  • [ISSN] 0165-5728
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NCI NIH HHS / CA / R01 CA097222; United States / NCI NIH HHS / CA / 1T32-CA-74736; United States / NCI NIH HHS / CA / CA-97222-0; United States / NCI NIH HHS / CA / T32 CA074736; United States / NCI NIH HHS / CA / 1P50CA108786-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS16766; NLM/ PMC1865509
  •  go-up   go-down


38. Perry J, Chambers A, Spithoff K, Laperriere N: Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol; 2007 Oct;14(5):189-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliadel wafers in the treatment of malignant glioma: a systematic review.
  • QUESTION: What is the safety and efficacy of interstitial chemotherapy with carmustine-loaded polymers (Gliadel wafers: MGI Pharma, Bloomington, MN, U.S.A.) in the treatment of newly diagnosed or recurrent malignant glioma (that is, glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligoastrocytoma, and anaplastic oligodendroglioma)?
  • PERSPECTIVES: Malignant glioma is the most common type of primary brain tumour in adults.
  • RESULTS: Two RCTS that compared Gliadel to placebo in patients with newly diagnosed malignant glioma were obtained.
  • One RCT and one prospective cohort study were obtained that examined the role of Gliadel in patients with recurrent malignant glioma.
  • CONCLUSIONS: Gliadel is an option for selected patients with newly diagnosed malignant glioma where a near gross total resection is possible.
  • Gliadel is also an option for patients with surgically resectable recurrent malignant glioma.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1999 Jul;45(1):17-22; discussion 22-3 [10414561.001]
  • [Cites] Surg Neurol. 2000 May;53(5):458-64 [10874145.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 [16482400.001]
  • (PMID = 17938702.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2002480
  • [Keywords] NOTNLM ; Gliadel / carmustine / glioblastoma / interstitial chemotherapy / malignant glioma / systematic review
  •  go-up   go-down


39. Hsieh D, Hsieh A, Stea B, Ellsworth R: IGFBP2 promotes glioma tumor stem cell expansion and survival. Biochem Biophys Res Commun; 2010 Jun 25;397(2):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGFBP2 promotes glioma tumor stem cell expansion and survival.
  • IGFBP2 is overexpressed in the most common brain tumor, glioblastoma (GBM), and its expression is inversely correlated to GBM patient survival.
  • Previous reports have demonstrated a role for IGFBP2 in glioma cell invasion and astrocytoma development.
  • However, the function of IGFBP2 in the restricted, self-renewing, and tumorigenic GBM cell population comprised of tumor-initiating stem cells has yet to be determined.
  • These results suggest that IGFBP2 is a selective malignant factor that may contribute significantly to GBM pathogenesis by enriching for GSCs and mediating their survival.
  • [MeSH-minor] Cell Line, Tumor. Cell Survival. Clone Cells. Enzyme Activation. Humans. Proto-Oncogene Proteins c-akt / metabolism. Transcription, Genetic

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20515648.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


40. Saikali S, Le Strat A, Heckly A, Stock N, Scarabin JM, Hamlat A: Multicentric pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1. Case report and review of the literature. J Neurosurg; 2005 Feb;102(2):376-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1. Case report and review of the literature.
  • The authors report an unusual case of multicentric pleomorphic xanthoastrocytoma (PXA) in a 36-year-old woman with neurofibromatosis Type 1 (NF1).
  • Although the occipital lesion was cured surgically, the cerebellar tumor recurred three times and underwent malignant transformation into an anaplastic oligodendroglioma.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Neurofibromatosis 1 / surgery
  • [MeSH-minor] Adult. Brain / pathology. Brain / surgery. Cell Transformation, Neoplastic / pathology. Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Cerebellum / pathology. Cerebellum / surgery. Disease Progression. Female. Humans. Image Enhancement. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Occipital Lobe / pathology. Occipital Lobe / surgery. Oligodendroglioma / pathology


41. Bäcklund LM, Nilsson BR, Liu L, Ichimura K, Collins VP: Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer; 2005 Jul 11;93(1):124-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas.
  • Anaplastic astrocytoma (AA, WHO grade III) is, second to Glioblastoma, the most common and most malignant type of adult CNS tumour.
  • The survival data on 37 carefully sampled AA was correlated with the results of a detailed analysis of the status of nine genes known to be involved in the development of astrocytic tumours.
  • We found that loss of both wild-type copies of any of the three tumour suppressor genes CDKN2A, CDKN2B and RB1 or gene amplification of CDK4, disrupting the Rb1 pathway, were associated with shorter survival (P=0.009).
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Genes, Retinoblastoma. Mutation


42. Oka F, Yamashita Y, Kumabe T, Tominaga T: Total resection of a hemorrhagic tectal pilocytic astrocytoma--case report. Neurol Med Chir (Tokyo); 2007 May;47(5):219-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total resection of a hemorrhagic tectal pilocytic astrocytoma--case report.
  • A 21-year-old man presented with a hemorrhagic pilocytic astrocytoma of the tectal plate manifesting as sudden onset of severe headache, vertigo, nausea, and vomiting.
  • Magnetic resonance (MR) imaging revealed a dorsally exophytic tectal tumor as hypointense on the T(1)-weighted image and hyperintense on the T(2)-weighted image with contrast enhancement.
  • Radical resection of the tumor was selected because of the unusual aggressive clinical course with hemorrhage and suspicion of malignant components.
  • The tumor was totally resected via an occipital transtentorial approach using a neuronavigation system without surgical complications.
  • The histological diagnosis was pilocytic astrocytoma.
  • Tectal plate pilocytic astrocytoma is rarely associated with hemorrhage but should be considered in the differential diagnosis of intracranial hemorrhage with acute presentation.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Intracranial Hemorrhages / etiology. Tectum Mesencephali

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527049.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Jang FF, Wei W, De WM: Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma. J Ayub Med Coll Abbottabad; 2008 Apr-Jun;20(2):105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.
  • BACKGROUND: Astrocytoma is the most malignant intracranial neoplasm and is characterized by high neovascularization and peritumoural brain oedema.
  • METHODS: The expression of two angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor were investigated using immunohistochemistry for astrocytoma from 82 patients and 11 normal human tissues.
  • RESULTS: The expression of vascular endothelial growth factor and basic fibroblast growth factor positively correlate with the pathological grade of astrocytoma, microvessel density numbers and brain oedema, which may be responsible for the increased tumour neovascularization and peritumoural brain oedema.
  • CONCLUSION: The results support the idea that inhibiting vascular endothelial growth factor and basic fibroblast growth factor are useful for the treatment of human astrocytoma and to improve patient's clinical outcomes and prognosis.
  • [MeSH-major] Astrocytoma / blood supply. Brain Edema / etiology. Brain Neoplasms / blood supply. Fibroblast Growth Factor 2 / biosynthesis. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385471.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


44. Pirotte BJ, Lubansu A, Massager N, Wikler D, Van Bogaert P, Levivier M, Brotchi J, Goldman S: Clinical interest of integrating positron emission tomography imaging in the workup of 55 children with incidentally diagnosed brain lesions. J Neurosurg Pediatr; 2010 May;5(5):479-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these, 55 presented with an incidental brain lesion and were selected for study because MR imaging sequences revealed limitations in assessing the tumor, its evolving nature, and/or the malignant potential of the lesion diagnosed.
  • 1) surgery in children with imaging evidence of increased PET tracer uptake, which is highly specific of tumor and/or malignant tumor tissue; or 2) conservative treatment in children in whom there was little or no tracer uptake on PET.
  • They studied PET and MR imaging sensitivity and specificity in detecting tumor and malignant tissues, and evaluated whether PET data altered their clinical management.
  • Tumor diagnosis was confirmed in all cases (that is, there were no false-positive findings).
  • Histological examination results demonstrated neither malignant nor evolving tumor tissue but yielded 9 indolent tumors (6 dysembryoplastic neuroectodermal tumors, 2 low-grade astrocytomas, and 1 low-grade astrocytoma and dysplasia) and 7 nontumoral lesions (3 cases of vasculitis, 3 of gliosis, and 1 of sarcoidosis).
  • Although an absence of PET tracer uptake might not exclude tumor tissue, PET did not reveal any false-negative findings in malignant or evolving tumor tissue detection in cases in which MR imaging showed false-positive and -negative cases in > 35 and 25% of the cases, respectively.
  • CONCLUSIONS: These data confirmed the high sensitivity and specificity of PET to detect tumor as well as malignant tissue.
  • Therefore, the risk of surgically treating a nontumoral lesion was reduced as well as that for conservatively managing a malignant tumor.


45. Raza SM, Garzon-Muvdi T, Boaehene K, Olivi A, Gallia G, Lim M, Subramanian P, Quinones-Hinojosa A: The supraorbital craniotomy for access to the skull base and intraaxial lesions: a technique in evolution. Minim Invasive Neurosurg; 2010 Feb;53(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intra-axial pathology ranged from anaplastic astrocytoma to metastasis while extra-axial lesions included meningiomas and skull-based metastases.
  • [MeSH-minor] Adenoma / surgery. Astrocytoma / surgery. Breast Neoplasms / surgery. Craniopharyngioma / surgery. Esthetics. Eyebrows. Eyelids. Female. Follow-Up Studies. Frontal Lobe / surgery. Humans. Male. Meningeal Neoplasms / surgery. Meningioma / surgery. Middle Aged. Pituitary Neoplasms / surgery. Postoperative Complications / etiology. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20376737.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Tanaka S, Kobayashi I, Utsuki S, Iwamoto K, Takanashi J: Biopsy of brain stem glioma using motor-evoked potential mapping by direct peduncular stimulation and individual adjuvant therapy. Case report. Neurol Med Chir (Tokyo); 2005 Jan;45(1):49-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Partial resection of the tumor was safely performed, with slight temporary neurological worsening.
  • The histological diagnosis was anaplastic astrocytoma.
  • Individual adjuvant therapy based on the results of real-time reverse transcription-polymerase chain reaction of O6-methylguanine-deoxyribonucleic acid methyltransferase achieved an almost complete tumor response.
  • [MeSH-major] Astrocytoma / surgery. Brain Mapping. Brain Stem Neoplasms / surgery. Evoked Potentials, Motor. Mesencephalon / physiopathology. Neurosurgical Procedures / methods

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699622.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Yaman E, Buyukberber S, Uner A, Coskun U, Akmansu M, Benekli M, Yamac D, Ozturk B, Kaya AO, Yildiz R, Ozkan S, Gunel N: Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. Onkologie; 2008 Jun;31(6):309-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
  • BACKGROUND: Surgical resection followed by radiotherapy used to be the standard treatment in malignant gliomas.
  • PATIENTS AND METHODS: Medical records of 64 patients with malignant glioma were reviewed.
  • Median progression-free survival, and overall survival have not yet been reached in the grade III astrocytoma group at a median follow-up of 19 months.
  • 2-year survival rates were 80% and 19% for the grade III astrocytoma, and for the glioblastoma multiforme groups, respectively.
  • Toxicity was mild to moderate with rare grade 4 toxicities.
  • CONCLUSION: Our data suggest that temozolomide is an active regimen for malignant gliomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2008 Jun;31(6):300-2 [18547969.001]
  • (PMID = 18547971.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


48. Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K, Huang S: FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res; 2008 Nov 1;68(21):8733-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously found that FoxM1B is overexpressed in human glioblastomas and that forced FoxM1B expression in anaplastic astrocytoma cells leads to the formation of highly angiogenic glioblastoma in nude mice.
  • Our findings provide both clinical and mechanistic evidence that FoxM1 contributes to glioma progression by enhancing VEGF gene transcription and thus tumor angiogenesis.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Feb;92(2):326-33 [10659021.001]
  • [Cites] Genes Dev. 2008 Feb 15;22(4):449-62 [18258752.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5879-86 [11059786.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4143-54 [11358838.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2058-65 [11960378.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):125-34 [12107097.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8404-13 [12466961.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] Semin Cancer Biol. 2004 Apr;14(2):123-30 [15018896.001]
  • [Cites] Genes Dev. 2004 Apr 1;18(7):830-50 [15082532.001]
  • [Cites] BMC Cancer. 2003 Sep 17;3:23 [13678425.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):941-51 [15184909.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Oct;15(5):297-324 [15450248.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Jan;53(1):11-21 [8301315.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):13333-40 [7768934.001]
  • [Cites] Circ Res. 1995 Sep;77(3):638-43 [7641334.001]
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5363-8 [7565686.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Pediatr Neurosurg. 1996;24(1):41-9 [8817614.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1626-41 [9032290.001]
  • [Cites] Nucleic Acids Res. 1997 May 1;25(9):1715-9 [9108152.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19827-36 [9242644.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3860-4 [9288800.001]
  • [Cites] Mol Biol Cell. 1998 Feb;9(2):469-81 [9450968.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):118-24 [10077162.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):162-7 [10328589.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):126-36 [15654331.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2065-9 [15781613.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):202-13 [15688401.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):134-53 [15831232.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22278-86 [15817462.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5181-9 [15958562.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1712-20 [16452231.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2153-61 [16489016.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3593-602 [16585184.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1420-31 [17408638.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8293-300 [17804744.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6212-9 [17404569.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2562-72 [10873113.001]
  • (PMID = 18974115.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA116528-03; United States / NCI NIH HHS / CA / CA116528-03; United States / NCI NIH HHS / CA / R01-CA-116528; United States / NCI NIH HHS / CA / R01 CA116528; United States / NCI NIH HHS / CA / R01 CA116528-02; United States / NCI NIH HHS / CA / CA116528-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS67455; NLM/ PMC2597644
  •  go-up   go-down


49. Tan G, Sun SQ, Yuan DL: Expression of the water channel protein aquaporin-9 in human astrocytic tumours: correlation with pathological grade. J Int Med Res; 2008 Jul-Aug;36(4):777-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the water channel protein aquaporin-9 in human astrocytic tumours: correlation with pathological grade.
  • This study investigated the expression of the water channel protein aquaporin-9 (AQP9) in 100 cases of human astrocytic tumour compared with normal brain tissue.
  • The expression of both AQP9 mRNA and protein in astrocytic tumours was significantly greater than in normal brain tissue and was positively correlated with pathological grade.
  • This study indicates that AQP9 may play an important role in the malignant progression of brain astrocytic tumours and may, therefore, be useful as a biomarker in its diagnosis and as a new target for gene therapy.
  • The molecular mechanisms by which AQP9 affects the proliferation and apoptosis of astrocytic tumours need to be studied further.
  • [MeSH-major] Aquaporins / metabolism. Astrocytoma. Brain Neoplasms

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652774.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AQP9 protein, human; 0 / Aquaporins
  •  go-up   go-down


50. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):156-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
  • The objectives of this study were to determine the safety and activity of this combination in malignant gliomas.
  • METHODS AND MATERIALS: After prior treatment with standard radiation therapy patients with recurrent glioblastoma (GBM) and anaplastic gliomas (AG) received bevacizumab (10 mg/kg intravenous) every 2 weeks of 28-day cycles until tumor progression.
  • Three patients discontinued treatment because of Grade 3 central nervous system intratumoral hemorrhage, wound dehiscence, and bowel perforation.
  • Radiographic responses, duration of disease control, and survival suggest that this regimen is active in recurrent malignant glioma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma. Brain Neoplasms. Neoplasm Recurrence, Local. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2004 Dec;27(6):646-8 [15577450.001]
  • [Cites] BMC Cancer. 2005;5:55 [15924621.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8136-9 [16258121.001]
  • [Cites] Neurosignals. 2005;14(5):207-21 [16301836.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):97-103 [16213059.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Acta Oncol. 2006;45(7):848-55 [16982549.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):39-44 [11196192.001]
  • [Cites] J Magn Reson Imaging. 2002 Mar;15(3):233-40 [11891967.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1399-405 [12684411.001]
  • [Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21 [15001240.001]
  • [Cites] Cancer Cell. 2004 May;5(5):429-41 [15144951.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):723-7 [3940638.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Radiother Oncol. 2007 Feb;82(2):185-90 [17257702.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):472-8 [17498568.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5076-82 [17545583.001]
  • [Cites] Trends Mol Med. 2007 Jun;13(6):223-30 [17462954.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):271-8 [18182667.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):193-205 [18328424.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):484-90 [18234445.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):324-5 [18474308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1372-80 [18355978.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):870-8 [17293237.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Magn Reson Med. 1992 Mar;24(1):174-6 [1556924.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):375-83 [9069310.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • (PMID = 19167838.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00595322
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ NIHMS460357; NLM/ PMC3659401
  •  go-up   go-down


51. Waha A, Felsberg J, Hartmann W, von dem Knesebeck A, Mikeska T, Joos S, Wolter M, Koch A, Yan PS, Endl E, Wiestler OD, Reifenberger G, Pietsch T, Waha A: Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res; 2010 Feb 15;70(4):1689-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Critical tumor suppression pathways in brain tumors have yet to be fully defined.
  • In 83 astrocytic gliomas and 5 glioma cell lines examined, hypermethylation of the MKP-2 promoter was found to occur relatively more frequently in diffuse or anaplastic astrocytomas and secondary glioblastomas relative to primary glioblastomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. DNA Methylation. Down-Regulation / physiology. Female. Gene Expression Regulation, Neoplastic / physiology. Gene Silencing / physiology. Genes, Tumor Suppressor / physiology. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124482.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.- / Mitogen-Activated Protein Kinase Phosphatases; EC 3.1.3.48 / DUSP4 protein, human; EC 3.1.3.48 / Dual-Specificity Phosphatases
  •  go-up   go-down


52. Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, Burns DK, Bajenaru ML, Gutmann DH, Parada LF: Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development; 2005 Dec;132(24):5577-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gene responsible for neurofibromatosis type 1 (NF1) encodes a tumor suppressor that functions as a negative regulator of the Ras proto-oncogene.
  • Individuals with germline mutations in NF1 are predisposed to the development of benign and malignant tumors of the peripheral and central nervous system (CNS).
  • Children with this disease suffer a high incidence of optic gliomas, a benign but potentially debilitating tumor of the optic nerve; and an increased incidence of malignant astrocytoma, reactive astrogliosis and intellectual deficits.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):361-7 [10931370.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]
  • [Cites] J Neurosci. 2005 Jun 8;25(23):5584-94 [15944386.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7773-9 [15520182.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4450-9 [10442636.001]
  • [Cites] Neuron. 2000 May;26(2):533-41 [10839371.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):557-64 [16069817.001]
  • [Cites] Development. 2000 Dec;127(24):5253-63 [11076748.001]
  • [Cites] Neuron. 2000 Oct;28(1):69-80 [11086984.001]
  • [Cites] Nature. 2001 Feb 8;409(6821):714-20 [11217860.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] Nat Rev Neurosci. 2001 Apr;2(4):287-93 [11283751.001]
  • [Cites] Neurology. 2001 Apr 10;56(7):885-90 [11294925.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):859-76 [11297510.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Genesis. 2001 Oct;31(2):85-94 [11668683.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):112-7 [11689956.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2085-91 [11929829.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] J Neurosci. 2002 Nov 1;22(21):9228-36 [12417648.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):751-64 [12628166.001]
  • [Cites] J Neurosci. 2003 Aug 6;23(18):7207-17 [12904481.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8573-7 [14695164.001]
  • [Cites] Neuron. 2004 Mar 25;41(6):881-90 [15046721.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Cell. 1990 Nov 16;63(4):835-41 [2121369.001]
  • [Cites] Cell. 1990 Nov 16;63(4):851-9 [2121371.001]
  • [Cites] Neuron. 1992 Mar;8(3):415-28 [1550670.001]
  • [Cites] Dev Dyn. 1992 Nov;195(3):216-26 [1301085.001]
  • [Cites] Dev Biol. 1994 Feb;161(2):538-51 [8314000.001]
  • [Cites] Neuron. 1994 Apr;12(4):895-908 [8161459.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Development. 1994 Sep;120(9):2637-49 [7956838.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):588-600 [7602332.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):453-64 [7593171.001]
  • [Cites] Development. 1995 Nov;121(11):3583-92 [8582272.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):862-72 [9001241.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] Trends Neurosci. 1997 Dec;20(12):570-7 [9416670.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] Brain Res. 1999 Jan 16;816(1):111-23 [9878702.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] J Neurosci. 1999 Feb 1;19(3):1049-61 [9920668.001]
  • (PMID = 16314489.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS052606-01; United States / NINDS NIH HHS / NS / P50 NS052606; United States / NINDS NIH HHS / NS / P50 NS052606-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1
  • [Other-IDs] NLM/ NIHMS149022; NLM/ PMC2760350
  •  go-up   go-down


53. Margareto J, Leis O, Larrarte E, Idoate MA, Carrasco A, Lafuente JV: Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways. J Mol Neurosci; 2007;32(1):53-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human malignant astrocytic tumors are the most common primary brain malignancies.
  • Human gliomas are classified according to the extent of anaplasia or 'de-differentiation' appearance.
  • Although this type of histological classification is widely accepted, the extensive heterogeneity of astrocytic tumors has made their pathological classification rather difficult.
  • New genome-scale high throughput technologies for gene expression profiling, such as DNA microarrays, are emerging as new tools to allow a more accurate identification and characterization of different tumor degrees by discovering new specific markers and pathways of each stage.
  • Present work reports interesting results that might be useful to differentiate between tumor grades.
  • Data presented here provides new evidences about the molecular basis underlying different tumor stages.
  • In this sense, we identified key metabolic pathways, crucial for tumor progression, as being differentially regulated in different tumor stages.
  • Our results clearly point out important molecular differences between different tumor stages and suggest that more studies are needed to understand specific molecular events characteristic of each stage.
  • These types of studies represent a first step to deepen into the tumor physiology, which may potentially help for better and a more precise diagnosis of gliomas.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / metabolism. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Glioblastoma / genetics. Glioblastoma / metabolism. Receptors, Notch / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2005 Jan;7(1):7-16 [15720813.001]
  • [Cites] Front Biosci. 2006 May 01;11:1414-24 [16368525.001]
  • [Cites] Neuron. 2001 Aug 30;31(4):557-68 [11545715.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] Crit Care. 2006;10(2):138 [16677407.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] Bioinformatics. 2005 Jul 1;21(13):2988-93 [15840702.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):123-33 [16193382.001]
  • [Cites] Bioinformatics. 2004 Mar 1;20(4):578-80 [14990455.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):466-76 [12496471.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Sep 1;215(2):208-17 [16580038.001]
  • [Cites] Cancer Biol Ther. 2005 Jul;4(7):759-62 [15970688.001]
  • [Cites] J Clin Neurosci. 2005 Nov;12(8):930-3 [16326273.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):756-67 [14570040.001]
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W472-6 [16845052.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6613-25 [14583454.001]
  • [Cites] Acta Neurochir Suppl. 2003;86:507-11 [14753496.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4051-8 [15899794.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):485-94 [16212813.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6868-74 [11156382.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6598-608 [14528285.001]
  • [Cites] Pediatr Res. 2005 May;57(5 Pt 2):104R-109R [15817497.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4228-32 [10485462.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9 [15827123.001]
  • [Cites] Annu Rev Neurosci. 2002;25:471-90 [12052917.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6082-90 [12203120.001]
  • [Cites] Mol Cancer Ther. 2004 Feb;3(2):129-36 [14985453.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10347-54 [16288024.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Br J Cancer. 1998;77(3):448-55 [9472642.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7794-800 [15520185.001]
  • (PMID = 17873288.001).
  • [ISSN] 0895-8696
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Notch
  •  go-up   go-down


54. Szeliga M, Matyja E, Obara M, Grajkowska W, Czernicki T, Albrecht J: Relative expression of mRNAS coding for glutaminase isoforms in CNS tissues and CNS tumors. Neurochem Res; 2008 May;33(5):808-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glutaminase (GA) in mammalian tissues occurs in three isoforms: LGA (liver-type), KGA (kidney-type) and GAC (a KGA variant).
  • Our previous study showed that human malignant gliomas (WHO grades III and IV) lack expression of LGA mRNA but are enriched in GAC mRNA relative to KGA mRNA.
  • Here we analyzed the expression of mRNAs coding for the three isoforms in the biopsy material derived from other central nervous system tumors of WHO grades I-III.
  • The GAC mRNA/KGA mRNA expression ratio was as a rule higher in the neoplastic than in control tissues, irrespective of the cell type dominating in the tumor or tumor malignancy.
  • LGA mRNA expression was relatively very low in cultured astrocytes, and very low to absent in astrocytoma pilocyticum, ependymoma and subependymal giant cell astrocytoma (SEGA), tumors of astrocytic origin.
  • The results show that low expression of LGA mRNA is a feature common to normal astrocytes and astroglia-derived tumor cells or ependymomas and can be considered as a cell-type, rather than a malignancy marker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroscience. 1999;88(4):1137-51 [10336125.001]
  • [Cites] Physiol Genomics. 2002;9(3):157-66 [12045296.001]
  • [Cites] Neurochem Int. 2006 May-Jun;48(6-7):465-71 [16516349.001]
  • [Cites] Physiol Genomics. 1999 Aug 31;1(2):51-62 [11015561.001]
  • [Cites] J Bioenerg Biomembr. 1998 Dec;30(6):565-78 [10206476.001]
  • [Cites] Neurochem Res. 1988 Apr;13(4):383-8 [2899301.001]
  • [Cites] Mol Cell Biochem. 1992 Jul 6;113(1):1-15 [1640933.001]
  • [Cites] Biochem J. 2000 Jun 1;348 Pt 2:257-61 [10816417.001]
  • [Cites] Neurosci Lett. 2005 Feb 21;374(3):171-3 [15663956.001]
  • [Cites] Biochem J. 2000 Jan 15;345 Pt 2:365-75 [10620514.001]
  • [Cites] Biochem J. 2003 Mar 1;370(Pt 2):403-8 [12408749.001]
  • [Cites] J Neurosci Res. 2001 Dec 1;66(5):951-8 [11746423.001]
  • [Cites] Annu Rev Nutr. 1995;15:133-59 [8527215.001]
  • [Cites] Biochem J. 2005 Mar 15;386(Pt 3):535-42 [15496140.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1192-4 [1346587.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38939-44 [12163477.001]
  • [Cites] Ann Surg. 1993 Dec;218(6):715-28 [8257221.001]
  • [Cites] FEBS Lett. 1994 Mar 14;341(1):39-42 [8137919.001]
  • (PMID = 17940881.001).
  • [ISSN] 0364-3190
  • [Journal-full-title] Neurochemical research
  • [ISO-abbreviation] Neurochem. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; EC 3.5.1.2 / Glutaminase
  •  go-up   go-down


55. Pavlisa G, Rados M, Pavlisa G, Pavic L, Potocki K, Mayer D: The differences of water diffusion between brain tissue infiltrated by tumor and peritumoral vasogenic edema. Clin Imaging; 2009 Mar-Apr;33(2):96-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The differences of water diffusion between brain tissue infiltrated by tumor and peritumoral vasogenic edema.
  • The differences between peritumoral brain tissue infiltrated by tumor and vasogenic edema were prospectively evaluated by comparing the apparent diffusion coefficient (ADC) of peritumoral areas of infiltrative tumors (anaplastic astrocytomas and glioblastomas) to that of peritumoral areas of noninfiltrative tumors (metastatic carcinomas) on 54 patients.
  • Peritumoral ADCs indicated the possibility of differentiation between tumor infiltration and vasogenic edema, as well as between primary gliomas and metastases.
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / pathology. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19237051.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Bien E, Stachowicz-Stencel T, Szalewska M, Krawczyk M, Synakiewicz A, Dubaniewicz-Wybieralska M, Zielinski P, Adamkiewicz-Drozynska E, Balcerska A: Poor-risk high-grade gliomas in three survivors of childhood acute lymphoblastic leukaemia--an overview of causative factors and possible therapeutic options. Childs Nerv Syst; 2009 May;25(5):619-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor-risk high-grade gliomas in three survivors of childhood acute lymphoblastic leukaemia--an overview of causative factors and possible therapeutic options.
  • PURPOSE: Malignant high-grade gliomas are the most common secondary neoplasms in children cured of acute lymphoblastic leukaemia (ALL).
  • METHODS: Three cases of secondary high-grade gliomas (two multiform glioblastomas, grade IV; one anaplastic astrocytoma, grade III) developed in ALL survivors (F-M, 1:2) 3 to 6.3 years after stopping ALL therapy according to BFM-90 trial.
  • Possible risk factors and current therapeutic options for paediatric ALL and malignant gliomas are reviewed and discussed.
  • CONCLUSIONS: Prognosis in secondary malignant gliomas in children is poor (overall survival of 5, 10 and 19 months) despite intense therapy.

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2009 Jul;25(7):779; author reply 781-2 [19452153.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3858-64 [16921038.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2701-7 [15226337.001]
  • [Cites] J Pediatr. 1991 Dec;119(6):985-9 [1960624.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(2):257-68 [17981026.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 May;26(5):1263-9 [15891195.001]
  • [Cites] J Clin Invest. 1992 Feb;89(2):640-7 [1737852.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4237-9 [7671227.001]
  • [Cites] Strahlenther Onkol. 2005 Jun;181(6):372-7 [15925979.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2497-502 [7595699.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7936-41 [16258093.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2257-66 [11187917.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:142-6 [17124053.001]
  • [Cites] Curr Opin Hematol. 2003 Jul;10(4):290-6 [12799535.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1798-809 [12721257.001]
  • [Cites] JAMA. 2007 Mar 21;297(11):1207-15 [17374815.001]
  • [Cites] Childs Nerv Syst. 2008 Jul;24(7):793-805 [18392837.001]
  • [Cites] Haematologica. 2003 May;88(5):555-60 [12745275.001]
  • [Cites] Childs Nerv Syst. 2007 Feb;23(2):185-93 [17021727.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Neurol India. 2004 Sep;52(3):375-7 [15472432.001]
  • [Cites] Cancer. 2008 May 15;112(10 ):2267-73 [18327820.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):817-24 [15305415.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):451-6 [7960210.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jan;42(1):24-9 [14752790.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):263-5 [9167750.001]
  • [Cites] Blood Cells Mol Dis. 2003 Jul-Aug;31(1):84-92 [12850490.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • (PMID = 19301014.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 30
  •  go-up   go-down


57. Oguzkan S, Terzi YK, Cinbis M, Anlar B, Aysun S, Ayter S: Molecular genetic analyses in neurofibromatosis type 1 patients with tumors. Cancer Genet Cytogenet; 2006 Mar;165(2):167-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic analyses in neurofibromatosis type 1 patients with tumors.
  • Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant disorders.
  • NF1 is clinically characterized by neurofibromas, pigmentation anomalies, and an increased risk of malignant tumors.
  • In addition, allelic loss of the NF1 locus was shown in a pilocytic astrocytoma.

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527612.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Fujimaki T, Ishii H, Matsuno A, Arai H, Nakagomi T: Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma. World J Surg Oncol; 2007;5:89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma.
  • BACKGROUND: Malignant gliomas recur even after extensive surgery and chemo-radiotherapy.
  • Here we report a patient with TMZ-refractory anaplastic astrocytoma (AA) who was treated successfully with a combination of interferon-beta and TMZ.
  • After 6 cycles, the tumor became refractory to TMZ, and the patient was treated with interferon-beta at 3 x 106 international units/body, followed by 5 consecutive days of 200 mg/m2 TMZ in cycles of 28 days.
  • After the second cycle the tumor decreased in size by 50% (PR).
  • The tumor showed further shrinkage after 8 months and the patient's KPS improved from 70% to 100%.
  • The immunohistochemical study of the initial tumor specimen confirmed positive MGMT protein expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3354-60 [10955823.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):613-24 [11290467.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] Neurol Med Chir (Tokyo). 2001 Mar;41(3):115-9; discussion 119-20 [11372553.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):175-81 [11995819.001]
  • [Cites] J Neurosurg. 2003 Dec;99(6):1047-52 [14705733.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7573-9 [16140920.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):172-9 [16323194.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Sep;33(9):1279-85 [16969025.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):1117-21 [17016602.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1155-60 [17024124.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):271-7 [17031561.001]
  • [Cites] Oncol Rep. 2006 Dec;16(6):1253-60 [17089046.001]
  • [Cites] J Interferon Res. 1990 Apr;10(2):141-51 [2140395.001]
  • [Cites] J Interferon Res. 1987 Jun;7(3):301-11 [3497213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4562-6 [7753843.001]
  • [Cites] Neurol Res. 2000 Dec;22(8):802-8 [11149242.001]
  • (PMID = 17683572.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1976115
  •  go-up   go-down


59. Murakami H, Sawa H, Kamada H: [Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors]. No To Shinkei; 2006 Jan;58(1):43-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors].
  • Cyclooxygenase (COX)-2 of astrocytic tumors was studied by immunohistochemistry.
  • COX-2 was expressed in 8 of 12 (75%) glioblastoma multiforme, 1 of 7 (14%) anaplastic astrocytoma, but none in astrocytoma.
  • The result showed that COX-2 expression may be related with histological grades and COX-2 inhibitors will be one of promising therapeutic tools in human astrocytic tumors.
  • [MeSH-major] Astrocytoma / enzymology. Cyclooxygenase 2 / analysis. Cyclooxygenase 2 Inhibitors / therapeutic use
  • [MeSH-minor] Adult. Aged. Etodolac / pharmacology. Female. Glioblastoma / drug therapy. Glioblastoma / enzymology. Humans. Immunoblotting. Immunohistochemistry. Male. Middle Aged. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482921.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; 2M36281008 / Etodolac; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


60. Shrivastava RK, Epstein FJ, Perin NI, Post KD, Jallo GI: Intramedullary spinal cord tumors in patients older than 50 years of age: management and outcome analysis. J Neurosurg Spine; 2005 Mar;2(3):249-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymoma was the most common tumor (83%), and 55% were located in the thoracic spine.
  • There were two deaths due tumor progression (both malignant tumors) and one recurrence (anaplastic astrocytoma).
  • All three patients in whom malignant astrocytomas were diagnosed underwent postoperative radiation therapy.
  • The authors recommend motor evoked potential-guided aggressive microsurgical resection, because the long-term outcome of benign lesions is excellent (good functional recovery and no tumor recurrence).
  • [MeSH-minor] Aged. Astrocytoma / surgery. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Quality of Life. Retrospective Studies. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796348.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Gu S, Bao N, Yin MZ: Combined fontanelle puncture and surgical operation in treatment of desmoplastic infantile astrocytoma: case report and a review of the literature. J Child Neurol; 2010 Feb;25(2):216-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined fontanelle puncture and surgical operation in treatment of desmoplastic infantile astrocytoma: case report and a review of the literature.
  • Desmoplastic infantile astrocytoma is a rare low-grade malignant brain tumor found in infants.
  • A case of desmoplastic infantile astrocytoma, including its clinical manifestations, pathological characteristics, differential diagnosis, treatment, and prognosis, is reported.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Cranial Fontanelles / surgery. Neurosurgical Procedures / methods


62. Tritschler I, Gramatzki D, Capper D, Mittelbronn M, Meyermann R, Saharinen J, Wick W, Keski-Oja J, Weller M: Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells. Int J Cancer; 2009 Aug 1;125(3):530-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells.
  • High biological activity of the transforming growth factor (TGF)-beta-Smad pathway characterizes the malignant phenotype of malignant gliomas and confers poor prognosis to glioma patients.
  • We report here that the levels of LTBP-1 protein in vivo increase with the grade of malignancy in gliomas.
  • LTBP-1 is associated with the ECM as well as secreted into the medium in cultured malignant glioma cells.
  • Collectively, we identify LTBP-1 as an important modulator of TGF-beta activation in glioma cells, which may contribute to the malignant phenotype of these tumors.
  • [MeSH-minor] Astrocytoma / metabolism. Cell Line, Tumor. Cell Proliferation. Extracellular Matrix / metabolism. Gene Expression Regulation, Neoplastic. Glioblastoma / metabolism. Humans. Immunoblotting. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. Phenotype. Phosphorylation. Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19431147.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LTBP1 protein, human; 0 / Latent TGF-beta Binding Proteins; 0 / SMAD2 protein, human; 0 / Smad2 Protein; 0 / Transforming Growth Factor beta
  •  go-up   go-down


63. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, Mabold JL, Edington HD, Butterfield LH, Whiteside TL, Potter DM, Schold SC Jr, Pollack IF: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med; 2007;5:67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.
  • BACKGROUND: The prognosis for malignant gliomas remains dismal.
  • METHODS: In University of Pittsburgh Cancer Institute (UPCI) protocol 95-033, adult participants with recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) received gross total resection (GTR) of the recurrent tumors, followed by two vaccinations with autologous fibroblasts retrovirally transfected with TFG-IL4-Neo-TK vector admixed with irradiated autologous glioma cells.
  • In UPCI 99-111, adult participants with newly diagnosed GBM or AA, following GTR and radiation therapy, received two intradermal vaccinations with the TFG-IL4-Neo-TK-transfected fibroblasts admixed with type-1 dendritic cells (DC) loaded with autologous tumor lysate.
  • Four other participants were withdrawn from the trial because of tumor progression prior to production of the cellular vaccine.
  • Moreover, both participants demonstrated clinical and radiological improvement with no evidence of allergic encephalitis, although both participants eventually succumbed with the tumor recurrence.
  • Nevertheless, successful generation of type-1 DCs and preliminary safety in the current study provide a strong rationale for further efforts to develop novel glioma vaccines.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 Jun 1;174(11):7194-201 [15905564.001]
  • [Cites] Gene Ther. 2005 May;12(9):733-41 [15772692.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5883-91 [16740728.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4478-87 [16618775.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Transl Med. 2007;5:10 [17295916.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6451-8 [17616706.001]
  • [Cites] Hum Gene Ther. 2000 Mar 1;11(4):637-53 [10724042.001]
  • [Cites] Cancer Gene Ther. 2000 Mar;7(3):486-94 [10766355.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):1877-81 [10925267.001]
  • [Cites] J Exp Med. 2000 Sep 18;192(6):823-33 [10993913.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):842-7 [11221866.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1848-54 [11251017.001]
  • [Cites] Hum Gene Ther. 2001 Mar 20;12(5):575-95 [11268289.001]
  • [Cites] Gene Ther. 2001 Aug;8(15):1157-66 [11509946.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):1054-60 [11600887.001]
  • [Cites] Brain Res Brain Res Rev. 2003 May;42(2):97-122 [12738053.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3188-92 [12789295.001]
  • [Cites] Blood. 2003 Jul 1;102(1):36-42 [12560234.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):13-20 [12952282.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3826-35 [14551301.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):218-27 [15102348.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5934-7 [15342370.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 [8097319.001]
  • [Cites] Hum Gene Ther. 1994 Jan;5(1):41-55 [8155771.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1995 May;17(4):238-48 [7582260.001]
  • [Cites] Hum Gene Ther. 1996 Mar 1;7(4):479-87 [8800742.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1096-103; discussion 1103-4 [8727138.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):762-6 [9579542.001]
  • [Cites] Forum (Genova). 1998 Oct-Dec;8(4):357-64 [9863030.001]
  • [Cites] Science. 1999 Feb 19;283(5405):1183-6 [10024247.001]
  • [Cites] Gene Ther. 1999 Feb;6(2):219-26 [10435106.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • (PMID = 18093335.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 207137-56-2 / Interleukin-4
  • [Other-IDs] NLM/ PMC2254376
  •  go-up   go-down


64. Niizuma K, Fujimura M, Kumabe T, Tominaga T: Malignant transformation of high-grade astrocytoma associated with neurocysticercosis in a patient with Turcot syndrome. J Clin Neurosci; 2007 Jan;14(1):53-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of high-grade astrocytoma associated with neurocysticercosis in a patient with Turcot syndrome.
  • A 45-year-old woman with anaplastic astrocytoma was clinically diagnosed with Turcot syndrome, and subsequently developed simultaneous neurocysticercosis and malignant transformation to glioblastoma.
  • The clinical course and histological findings suggest that the parasitic infection and/or genetic changes contributed to the malignant transformation of the astrocytic tumour.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioblastoma / pathology. Neurocysticercosis / pathology

  • Genetic Alliance. consumer health - Turcot syndrome.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17138070.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


65. Kruer MC, Kaplan AM, Etzl MM Jr, Carpentieri DF, Dickman PS, Chen K, Mathieson K, Irving A: The value of positron emission tomography and proliferation index in predicting progression in low-grade astrocytomas of childhood. J Neurooncol; 2009 Nov;95(2):239-245
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of positron emission tomography and proliferation index in predicting progression in low-grade astrocytomas of childhood.
  • Astrocytomas are the most common brain tumors of childhood and adolescence.
  • Low-grade astrocytomas (LGAs), in general, have favorable prognosis, but recurrence or progressive disease with dissemination, malignant transformation, and death occur in some cases.
  • Current clinical and pathological measures including age, sex, imaging characteristics, location and size of the tumor, histopathology, and degree of resection cannot predict with certainty which tumors will demonstrate aggressive behavior.
  • We reviewed 46 cases ages 5 months to 17 years with low-grade (WHO I-II) astrocytomas.
  • [MeSH-major] Astrocytoma / diagnostic imaging. Brain Neoplasms / diagnostic imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals


66. Tsuboi Y, Kurimoto M, Nagai S, Kamiyama H, Endo S: Malignant transformation of oligoastrocytoma: a case report. Brain Tumor Pathol; 2007;24(2):63-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of oligoastrocytoma: a case report.
  • We report a case of oligoastrocytoma resembling dysembryoplastic neuroepithelial tumor (DNT) with malignant transformation.
  • Magnetic resonance imaging (MRI) revealed an extensive left temporal lobe tumor.
  • She underwent partial resection of the tumor under awake surgery, while preserving her language function.
  • The surgical specimen showed that the majority of the tumor was composed of a glioneuronal element.
  • The tumor recurred at the left temporal lobe in June 2005.
  • The pathological diagnosis was anaplastic oligoastrocytoma with a MIB-1 staining index of 79%.
  • She received PAV (procarvazine, ACNU, and vincristine) chemotherapy, and the tumor subsided transiently.
  • The authors concluded that this tumor could be a malignant transformation of oligoastrocytoma mimicking DNT, and we wish to give warning that the presence of a glioneuronal component is not an absolute benign hallmark.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Neuroectodermal Tumors, Primitive / pathology

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095133.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


67. Anselmo NP, Rey JA, Almeida LO, Custódio AC, Almeida JR, Clara CA, Santos MJ, Casartelli C: Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma. Genet Mol Res; 2009;8(4):1257-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma.
  • Disruption or loss of tumor suppressor gene TP53 is implicated in the development or progression of almost all different types of human malignancies.
  • Using PCR-SSCP and gene sequencing, we analyzed the TP53 and TP73 genes in a case of a grade III anaplastic astrocytoma that progressed to glioblastoma.
  • The mutation found at exon 6 of the gene TP53 could be associated with the rapid tumoral progression found in this case, since the mutated p53 may inactivate the wild-type p53 and the p73alpha protein, which was conserved here, leading to an increase in cellular instability.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876867.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


68. Rosenfeld A, Listernick R, Charrow J, Goldman S: Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst; 2010 May;26(5):663-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 1 and high-grade tumors of the central nervous system.
  • PURPOSE: Neurofibromatosis type 1 (NF1), a common genetic disorder, predisposes patients to the development of both benign and malignant tumors.
  • Although the most common central nervous system (CNS) tumor is a low-grade pilocytic astrocytoma of the optic pathway, there have been sporadic reports of NF1 patients with more aggressive CNS lesions.
  • METHODS: We conducted a retrospective review of all patients with NF1 and any CNS tumor being followed in the Children's Memorial Hospital NF1 Clinic.
  • Five patients (3%) were identified as having high-grade tumors, which consisted of anaplastic medulloblastoma (n = 1) and high-grade glioma (n = 4).
  • Three of the five patients had a history of an OPT prior to the development of their high-grade lesions.
  • CONCLUSION: High-grade CNS tumors may occur in children with NF1.


69. Shamji MF, Vassilyadi M, Lam CH, Montes JL, Farmer JP: Congenital tumors of the central nervous system: the MCH experience. Pediatr Neurosurg; 2009;45(5):368-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant histology is common, with persistently poor outcomes despite accessible neuroimaging and evolving adjuvant therapy.
  • METHODS: A retrospective review was performed of congenital brain tumor patients surgically treated at the Montreal Children's Hospital (MCH) over a 22-year period.
  • Median age (p = 0.93) and gender (p = 0.57) did not differ by location, and predominant histologies were choroid plexus papilloma and primitive neuroectodermal tumor.
  • CONCLUSIONS: Congenital brain tumor patients represent fewer than 2% of patients treated at MCH.
  • [MeSH-major] Brain Neoplasms / surgery. Decompression, Surgical. Laminectomy. Papilloma, Choroid Plexus / surgery. Rhabdoid Tumor / surgery. Spinal Neoplasms / surgery
  • [MeSH-minor] Astrocytoma / congenital. Astrocytoma / mortality. Astrocytoma / surgery. Cerebellar Neoplasms / congenital. Cerebellar Neoplasms / mortality. Cerebellar Neoplasms / surgery. Female. Follow-Up Studies. Hospitals, Pediatric / statistics & numerical data. Humans. Infant. Infant, Newborn. Male. Medulloblastoma / congenital. Medulloblastoma / mortality. Medulloblastoma / surgery. Neuroectodermal Tumors, Primitive / congenital. Neuroectodermal Tumors, Primitive / mortality. Neuroectodermal Tumors, Primitive / surgery. Ontario / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19907201.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


70. Chen FX, Qian YR, Duan YH, Ren WW, Yang Y, Zhang CC, Qiu YM, Ji YH: Down-regulation of 67LR reduces the migratory activity of human glioma cells in vitro. Brain Res Bull; 2009 Aug 14;79(6):402-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Glioma is the most common brain tumor in central nervous system.
  • Experimental evidence indicates that the 67 kDa elastin-laminin receptor (67LR) subunit is a high-affinity non-integrin laminin-binding protein that is over-expressed on the tumor cell surface in a variety of human carcinomas, and directly correlates with a higher proliferation rate of malignant cells and tendency to metastasize.
  • METHODS: In this study, we estimated whether 67LR was constitutively over-expressed in high-grade astrocytomas by immunohistochemical staining and Western blotting, and investigated the role of a low level of 67LR expression in glioma cell line-U251 by constructing an interfering RNA expression plasmid.
  • RESULTS: The results showed that the 67LR had an enhanced over-expression in high-grade astrocytomas against normal brain tissues samples, and that the migratory activity of glioma cells was reduced after the down-regulation of the 67LR gene by RNAi.
  • DISCUSSION: It was hypothesized that a low level of 67LR expression could reduce migratory activity of glioma cells, which further proved that 67LR played an important role in glioma invasion by mediating tumor cell functions leading to sarcomata.
  • [MeSH-major] Astrocytoma / physiopathology. Brain Neoplasms / physiopathology. Cell Movement / physiology. Glioma / physiopathology. Receptors, Laminin / metabolism
  • [MeSH-minor] Blotting, Western. Brain / metabolism. Cell Line, Tumor. Down-Regulation. Humans. Immunohistochemistry. Neoplasm Staging. Photomicrography. RNA Interference. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19446013.001).
  • [ISSN] 1873-2747
  • [Journal-full-title] Brain research bulletin
  • [ISO-abbreviation] Brain Res. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Laminin
  •  go-up   go-down


71. Takei H, Adesina AM, Powell SZ: Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex. Neuropathology; 2009 Apr;29(2):181-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex.
  • Subependymal giant cell astrocytoma (SEGA) is a benign, slowly growing tumor typically occurring in the setting of tuberous sclerosis complex (TSC).
  • The patient had a history of radical vulvectomy for malignant melanoma (MM), and died of autopsy-confirmed widespread systemic metastasis.
  • Histologically, it was composed of interlacing bundles of spindle-shaped tumor cells with thin delicate processes admixed with relatively large pleomorphic cells with abundant glassy eosinophilic cytoplasm, as seen in a SEGA.
  • Immunohistochemically, GFAP, S-100 protein, and neuron specific enolase were positive, and synaptophysin labeled a few tumor cells.
  • Also noted were rare isolated MM cells within the tumor (i.e., tumor-to-tumor metastasis).
  • Tumor metastasis to an occult SEGA is extremely rare.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Aged. Autopsy. Brain / pathology. Brain / physiopathology. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Melanoma / pathology. Melanoma / physiopathology. Melanoma / secondary. Neoplasm Metastasis. Phosphopyruvate Hydratase / metabolism. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673443.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


72. Zhang K, Li C, Liu Y, Li L, Ma X, Meng X, Feng D: Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2. Neuroradiology; 2007 Nov;49(11):913-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2.
  • INTRODUCTION: Even low-grade astrocytomas infiltrate the entire brain, a feature that precludes their successful therapy.
  • So to assess the invasive potential of astrocytoma is very important.
  • The aim of this study was determine whether there is a significant correlation between the results of (1)H-magnetic resonance spectroscopy ((1)H-MRS) and tumor invasive potential of astrocytoma, which is reflected by expression of matrix metalloproteinase-2 (MMP-2).
  • METHODS: The (1)H-MRS spectra of 41 histologically verified astrocytomas were obtained on a 3-T MR scanner.
  • According to the World Health Organization classification criteria for central nervous system tumors, there were 16 low-grade astrocytomas (2 pilocytic astrocytomas, 14 grade II astrocytomas) and 25 high-grade astrocytomas (5 anaplastic astrocytomas, 20 glioblastomas).The choline/N-acetylaspartate (Cho/NAA) and choline/creatine (Cho/Cr) ratios were calculated.
  • Of the 41 astrocytomas, 19 (8 low-grade and 11 high-grade) were analyzed immunohistochemically.
  • The correlations between metabolite ratios and the quantitative data from the immunohistochemical tests in the 19 astrocytomas were determined.
  • RESULTS: The Cho/NAA and Cho/Cr ratios of high-grade astrocytoma were both significantly greater than those of low-grade astrocytoma (t = -6.222, P = 0.000; t = -6.533, P = 0.000, respectively).
  • MMP-2 COD values of high-grade astrocytomas were also significantly greater than those of low-grade astrocytomas (t = -5.892, P = 0.000).
  • CONCLUSION: (1)H-MRS is helpful in evaluating the invasiveness of astrocytomas and predicting prognosis preoperatively by determining the Cho/NAA and Cho/Cr ratios.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Magnetic Resonance Spectroscopy. Matrix Metalloproteinase 2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Choline / metabolism. Creatine / metabolism. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):207-14 [11994741.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):495-502 [10571411.001]
  • [Cites] Neuroradiology. 2006 May;48(5):312-8 [16552583.001]
  • [Cites] Radiology. 2006 Mar;238(3):958-69 [16424238.001]
  • [Cites] Pharmacol Res. 2002 Aug;46(2):155-63 [12220955.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] NMR Biomed. 2004 Feb;17(1):10-20 [15011246.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8904-9 [12861074.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):117-23 [9974066.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):52-5 [10638966.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):233-45 [12892229.001]
  • [Cites] Stereotact Funct Neurosurg. 2004;82(2-3):90-7 [15305081.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):429-37 [9708803.001]
  • [Cites] Neuroradiology. 2002 May;44(5):371-81 [12012120.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] Nat Rev Neurosci. 2001 Jul;2(7):502-11 [11433375.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Nov-Dec;23 (10 ):1775-8 [12427638.001]
  • (PMID = 17763847.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; EC 3.4.24.24 / Matrix Metalloproteinase 2; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


73. Xiang C, Sarid R, Cazacu S, Finniss S, Lee HK, Ziv-Av A, Mikkelsen T, Brodie C: Cloning and characterization of human RTVP-1b, a novel splice variant of RTVP-1 in glioma cells. Biochem Biophys Res Commun; 2007 Oct 26;362(3):612-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, RTVP-1 and RTVP-1b showed similar patterns of expression in astrocytic tumors; highly expressed in glioblastomas as compared to normal brains, low-grade astrocytomas and anaplastic oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Glioma / metabolism. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Alternative Splicing. Amino Acid Sequence. Base Sequence. Cell Line, Tumor. Cell Movement. Cell Proliferation. Cloning, Molecular. Humans. Molecular Sequence Data. Protein Isoforms. Tissue Distribution

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825796.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-R21-96965; United States / NCI NIH HHS / CA / R24 CA095809
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLIPR1 protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms
  •  go-up   go-down


74. Argyriou AA, Giannopoulou E, Kalofonos HP: Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Oncology; 2009;77(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
  • Angiogenesis is considered to be a regulating factor of vascular development and growth for malignant gliomas, including glioblastoma multiforme (GBM) and anaplastic astrocytomas.
  • The VEGF/VEGFR-2 is the predominant angiogenic signalling pathway in malignant gliomas.
  • Our aim is to review current knowledge on angiogenesis as a molecular pathogenetic mechanism of malignant gliomas and to critically look at and discuss antiangiogenic molecularly targeted therapies for these brain malignancies.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19439998.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  • [Number-of-references] 98
  •  go-up   go-down


75. Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J, Hayashi Y: Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol; 2005 Mar;109(3):294-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DcR3 has been demonstrated to produce a secreted member of the tumor necrosis factor receptor superfamily that negatively regulates Fas-mediated apoptosis.
  • In this study we examined DcR3 gene amplification, DcR3 mRNA expression, and DcR3 protein expression in 46 human astrocytic brain tumors by quantitative genomic PCR, quantitative reverse transcription-PCR, and immunohistochemistry, respectively.
  • The DcR3 gene amplification was detected in none of 6 (0%) low-grade astrocytomas, 1 of 16 (6%) anaplastic astrocytomas, and 6 of 24 ( 25%) glioblastomas.
  • We thus concluded that high DcR3 mRNA expression and protein expression may be positively related to the gene amplification in astrocytic brain tumors, especially glioblastomas.
  • Further, we speculated that the DcR3 gene amplification with overexpression may be responsible for malignant features in glioblastomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. RNA, Messenger / biosynthesis. Receptors, Tumor Necrosis Factor. Receptors, Tumor Necrosis Factor, Member 6b. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627206.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human
  •  go-up   go-down


76. Rao SA, Santosh V, Somasundaram K: Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol; 2010 Oct;23(10):1404-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma.
  • Malignant astrocytoma includes anaplastic astrocytoma (grade III) and glioblastoma (grade IV).
  • Among them, glioblastoma is the most common primary brain tumor with dismal responses to all therapeutic modalities.
  • We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.
  • More importantly, we identified a most discriminatory 23-miRNA expression signature, by using PAM, which precisely distinguished glioblastoma from anaplastic astrocytoma with an accuracy of 95%.
  • The differential expression pattern of nine miRNAs was further validated by real-time RT-PCR on an independent set of malignant astrocytomas (n=72) and normal samples (n=7).
  • Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. MicroRNAs / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20711171.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down


77. Limentani SA, Asher A, Heafner M, Kim JW, Fraser R: A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol; 2005 May;72(3):241-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
  • Two types of chemotherapy used in the treatment of patients with malignant glioma are carboplatin and Gliadel wafer [(3.85% 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)].
  • The purpose of this study was to evaluate combination chemotherapy with Gliadel wafer and carboplatin in patients with high-grade, malignant glioma.
  • Fourteen (88%) patients had glioblastoma multiforme and 2 (12%) had anaplastic astrocytoma.
  • No grade 3 or 4 toxicities were noted in this study.
  • We conclude that administering systemic carboplatin is safe and well tolerated in the postoperative period immediately following resection and implantation of Gliadel wafer for the treatment of malignant glioma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Carboplatin / therapeutic use. Decanoic Acids / therapeutic use. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Polyesters / therapeutic use
  • [MeSH-minor] Adult. Aged. Carmustine. Combined Modality Therapy. Disease Progression. Drug Implants. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):619-25 [11148660.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Neurosurgery. 1992 Feb;30(2):223-7 [1312230.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):672-84 [9485020.001]
  • [Cites] J Neurosurg. 1992 May;76(5):772-81 [1564540.001]
  • [Cites] Neuro Oncol. 2001 Oct;3(4):246-50 [11584894.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(4):376-9 [9025780.001]
  • [Cites] J Control Release. 1999 Aug 27;61(1-2):21-41 [10469900.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 15937647.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Drug Implants; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


78. Krzyszkowski T, Dziedzic T, Czepko R, Szczudlik A: Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma. Neurol Res; 2008 Apr;30(3):294-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma.
  • It is unknown if production of these cytokines is limited to the site of tumor or these molecules are also released to cerebrospinal fluid and blood.
  • The goal of our study was to determine if patients with astrocytoma have increased levels of IL-10 and TGF-beta 2 in cerebrospinal fluid (CSF) and serum.
  • METHODS: CSF and serum samples were taken from 16 patients with astrocytoma of grade III or grade IV according to the WHO classification and from 28 age- and gender-matched controls (patients with normal pressure hydrocephalus or with lumbar disk herniation).
  • Patients with astrocytoma had decreased levels of IL-10 (0.9 +/- 1.2 versus 3.5 +/- 9.2 pg/ml, p=0.01) and TGF-beta 2 (0.0 +/- 0.0 versus 5.4 +/- 9.4 pg/ml, p=0.05) in CSF compared to controls.
  • Because serum IL-10 and TGF-beta 2 levels are similar in patients with astrocytoma and in controls, these cytokines are probably not directly involved in peripheral monocyte and T cell deactivation.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / cerebrospinal fluid. Interleukin-10 / blood. Interleukin-10 / cerebrospinal fluid. Transforming Growth Factor beta2 / blood. Transforming Growth Factor beta2 / cerebrospinal fluid

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848206.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta2; 130068-27-8 / Interleukin-10
  •  go-up   go-down


79. Keshavarzi S, Meltzer H, Ben-Haim S, Newman CB, Lawson JD, Levy ML, Murphy K: Initial clinical experience with frameless optically guided stereotactic radiosurgery/radiotherapy in pediatric patients. Childs Nerv Syst; 2009 Jul;25(7):837-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were treated for juvenile pilocytic astrocytoma (JPA; n = 2), pontine low-grade astrocytoma (n = 1), pituitary adenoma (n = 3), metastatic medulloblastoma (n = 1), acoustic neuroma (n = 1), and pineocytoma (n = 1).
  • CONCLUSION: Frameless stereotactic optically guided radiosurgery and radiotherapy provides a feasible and accurate tool to treat a number of benign and malignant tumors in children with minimal treatment-related morbidity.
  • [MeSH-minor] Adolescent. Astrocytoma / pathology. Astrocytoma / radiotherapy. Astrocytoma / surgery. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Medulloblastoma / radiotherapy. Medulloblastoma / surgery. Neoplasm Metastasis / radiotherapy. Pineal Gland / pathology. Pineal Gland / surgery. Pinealoma / radiotherapy. Pinealoma / surgery. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery. Prolactinoma / radiotherapy. Prolactinoma / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2001 May;17(6):341-6; discussion 347 [11417414.001]
  • [Cites] Pediatr Neurol. 1996 Oct;15(3):193-9 [8916155.001]
  • [Cites] Med Phys. 2002 Aug;29(8):1729-38 [12201420.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):140-6; discussion 146-7 [12493111.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):585-97 [14628124.001]
  • [Cites] Neurosurgery. 2004 Jul;55(1):89-98; discussion 98-9 [15214977.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):916-24; discussion 924-5 [15458600.001]
  • [Cites] Br J Neurosurg. 1989;3(3):305-12 [2506900.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(4-5):219-21 [2135190.001]
  • [Cites] Neurosurg Clin N Am. 1992 Jan;3(1):167-90 [1633445.001]
  • [Cites] Acta Neurochir Suppl. 1994;62:83-7 [7717143.001]
  • [Cites] J Neurosurg Anesthesiol. 1995 Apr;7(2):100-8 [7772962.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):696-701; discussion 701-2 [8692387.001]
  • [Cites] Pediatr Neurosurg. 1996;24(3):139-44 [8870017.001]
  • [Cites] Pediatr Neurosurg. 1996;24(4):193-201 [8873161.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):875-82 [9240657.001]
  • [Cites] Anaesth Intensive Care. 1997 Dec;25(6):691-5 [9452856.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):573-80 [9806517.001]
  • [Cites] Neurosurg Clin N Am. 1999 Apr;10(2):181-202 [10099088.001]
  • [Cites] Nature. 1958 Nov 1;182(4644):1222-3 [13590280.001]
  • [Cites] Childs Nerv Syst. 2005 Apr;21(4):301-7; discussion 308 [15654635.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1467-72 [15817352.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):304-10 [15558704.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):914-21 [16338096.001]
  • [Cites] NeuroRx. 2006 Apr;3(2):276-91 [16554265.001]
  • [Cites] Cancer Radiother. 2006 Sep;10(5):283-7 [16859948.001]
  • [Cites] Semin Oncol Nurs. 2006 Nov;22(4):221-32 [17095398.001]
  • [Cites] Med Dosim. 2007 Summer;32(2):121-33 [17472891.001]
  • [Cites] Cancer J. 2007 Mar-Apr;13(2):87-94 [17476136.001]
  • [Cites] Neurosurgery. 2007 Sep;61(3 Suppl):130-40; discussion 140-1 [17876243.001]
  • [Cites] Clin Lung Cancer. 2007 Sep;8(8):488-92 [17922973.001]
  • [Cites] Med Phys. 2007 Oct;34(10):3962-70 [17985641.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1507-15 [18020920.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Dec;7(12 Suppl):S69-77 [18076312.001]
  • [Cites] J Clin Anesth. 2007 Dec;19(8):616-8 [18083476.001]
  • [Cites] Neurosurg Focus. 2007;23(6):E4 [18081481.001]
  • [Cites] Neurosurg Focus. 2007;23(6):E5 [18081482.001]
  • [Cites] J Neurosurg Pediatr. 2008 Apr;1(4):296-304 [18377305.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008;71(1 Suppl):S131-5 [18406912.001]
  • [Cites] Neurosurgery. 2008 Mar;62(3):647-55; discussion 647-55 [18425011.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1152-8 [11704340.001]
  • (PMID = 19326128.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2691523
  •  go-up   go-down


80. Wagner S, Csatary CM, Gosztonyi G, Koch HC, Hartmann C, Peters O, Hernáiz-Driever P, Théallier-Janko A, Zintl F, Längler A, Wolff JE, Csatary LK: Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS; 2006 Oct;114(10):731-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid.
  • The case of a 12-year-old boy with anaplastic astrocytoma of the left thalamus is reported.
  • Postoperative irradiation and chemotherapy could not repress tumor progression; therefore, treatment was undertaken with an oncolytic virus, MTH-68/H, an attenuated strain of Newcastle disease virus (NDV), and valproic acid (VPA), an antiepileptic drug, which also has antineoplastic properties.
  • This treatment resulted in a far-reaching regression of the thalamic glioma, but 4 months later a new tumor manifestation, an extension of the thalamic tumor, appeared in the wall of the IVth ventricle, which required a second neurosurgical intervention.
  • Under continuous MTH-68/H - VPA administration the thalamic tumor remained under control, but the rhombencephalic one progressed relentlessly and led to the fatal outcome.
  • In the final stage, a third tumor manifestation appeared in the left temporal lobe.
  • The possible reasons for the antagonistic behavior of the three manifestations of the same type of glioma to the initially most successful therapy are discussed.
  • The comparative histological study of the thalamic and rhombencephalic tumor manifestations revealed that MTH-68/H treatment induces, similar to in vitro observations, a massive apoptotic tumor cell decline.
  • In the rhombencephalic tumor, in and around the declining tumor cells, NDV antigen could be demonstrated immunohistochemically, and virus particles have been found in the cytoplasm of tumor cells at electron microscopic investigation.
  • [MeSH-major] Anticonvulsants / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / therapy. Brain Neoplasms / therapy. Valproic Acid / therapeutic use. Viral Vaccines / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004977.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antigens, Viral; 0 / Newcastle disease virus vaccine MTH-68-H; 0 / Viral Vaccines; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


81. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol; 2010 Jan;20(1):245-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterozygous point mutations of isocitrate dehydrogenase (IDH)1 codon 132 are frequent in grade II and III gliomas.
  • Here we investigate the capability of this antibody to differentiate wild type and mutated IDH1 protein in central nervous system (CNS) tumors by Western blot and immunohistochemistry.
  • Intriguing is the ability of mIDH1R132H to detect single infiltrating tumor cells.
  • The very high frequency and the distribution of this mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma World Health Organization (WHO) grade II from pilocytic astrocytoma or ependymoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Ependymoma / genetics. Glioma / enzymology. Glioma / genetics. Isocitrate Dehydrogenase / genetics. Isocitrate Dehydrogenase / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigen-Antibody Reactions. Blotting, Western. Child. Child, Preschool. Cloning, Molecular. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Mutation / genetics. Mutation / physiology. Protein Biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19903171.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


82. Schittenhelm J, Mittelbronn M, Nguyen TD, Meyermann R, Beschorner R: WT1 expression distinguishes astrocytic tumor cells from normal and reactive astrocytes. Brain Pathol; 2008 Jul;18(3):344-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 expression distinguishes astrocytic tumor cells from normal and reactive astrocytes.
  • Particularly in small brain biopsies, it might be difficult to distinguish reactive astrogliosis from low-grade or infiltration zones of high-grade astrocytomas.
  • Recently, the over-expression of Wilms' tumor gene product WT1 was reported in astrocytic tumor cells.
  • Therefore, we investigated WT1 expression in paraffin-embedded brain sections from 28 controls, 48 cases with astrogliosis of various etiology and 219 astrocytomas [World Health Organization (WHO) grades I-IV] by immunohistochemistry.
  • In astrocytomas, WT1-positive tumor cells were found in pilocytic astrocytomas (66.7% of cases), diffuse astrocytomas (52.7%) WHO grade II (52.7%), anaplastic astrocytomas (83.4%) and glioblastomas (98.1%).
  • Overall, the majority of all astrocytic neoplasms (84.5%) expressed WT1.
  • Establishing a cut-off value of 0% immunoreactive tumor cells served to recognize neoplastic astrocytes with 100% specificity and 68% sensitivity and was associated with positive and negative predictive values of 1 and 0.68, respectively.
  • [MeSH-major] Astrocytes / metabolism. Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gliosis / metabolism. WT1 Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Endothelial Cells / metabolism. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18371184.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / WT1 Proteins
  •  go-up   go-down


83. Stella N: Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia; 2010 Jul;58(9):1017-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.
  • These receptors are expressed by microglia, astrocytes and astrocytomas, and their activation regulates these cells' differentiation, functions and viability.
  • This review summarizes this evidence, and discusses how selective compounds targeting cannabinoid-like receptors constitute promising therapeutics to manage neuroinflammation and eradicate malignant astrocytomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • [Cites] Neuropharmacology. 2002 Sep;43(4):503-10 [12367597.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16511-6 [19805329.001]
  • [Cites] Nat Neurosci. 2009 Dec;12(12):1488-90 [19915567.001]
  • [Cites] Pharmacol Ther. 2005 May;106(2):133-45 [15866316.001]
  • [Cites] Life Sci. 2005 Aug 19;77(14):1685-98 [15963531.001]
  • [Cites] Life Sci. 2005 Aug 19;77(14):1674-84 [16005906.001]
  • [Cites] J Neurochem. 2005 Oct;95(2):437-45 [16086683.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):61-70 [14708026.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Mar;308(3):838-45 [14617682.001]
  • [Cites] Neuropharmacology. 2004 Apr;46(5):709-15 [14996548.001]
  • [Cites] J Neurochem. 2004 Mar;88(5):1159-67 [15009671.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):294-9 [14963641.001]
  • [Cites] Mol Pharmacol. 2004 Apr;65(4):999-1007 [15044630.001]
  • [Cites] J Med Chem. 2004 Jul 15;47(15):3800-6 [15239658.001]
  • [Cites] Synapse. 2004 Sep 15;53(4):208-13 [15266552.001]
  • [Cites] Cell Signal. 2005 Jan;17(1):25-37 [15451022.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Sep;63(9):956-63 [15453094.001]
  • [Cites] Experientia. 1973;29(7):825-6 [4724713.001]
  • [Cites] Experientia. 1973 Nov 15;29(11):1368-9 [4761242.001]
  • [Cites] J Nat Prod. 1980 Mar-Apr;43(2):169-234 [6991645.001]
  • [Cites] Nature. 1990 Aug 9;346(6284):561-4 [2165569.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):3825-9 [1315042.001]
  • [Cites] Nature. 1993 Sep 2;365(6441):61-5 [7689702.001]
  • [Cites] FEBS Lett. 1994 Aug 22;350(2-3):240-4 [8070571.001]
  • [Cites] J Biol Chem. 1995 Jun 9;270(23):13973-80 [7775459.001]
  • [Cites] Neurosci Lett. 1995 Feb 17;186(2-3):91-4 [7777206.001]
  • [Cites] Nature. 1995 Aug 17;376(6541):590-4 [7637807.001]
  • [Cites] Mol Pharmacol. 2006 Jul;70(1):101-11 [16611855.001]
  • [Cites] AAPS J. 2006;8(2):E272-6 [16796377.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):197-203 [16804518.001]
  • [Cites] J Clin Invest. 2009 May;119(5):1359-72 [19425170.001]
  • [Cites] FEBS Lett. 2009 Jun 18;583(12):2071-6 [19464294.001]
  • [Cites] Nat Neurosci. 2009 Sep;12(9):1152-8 [19648913.001]
  • [Cites] Science. 2009 Sep 11;325(5946):1349-51 [19745140.001]
  • [Cites] Glia. 1996 Sep;18(1):1-10 [8891687.001]
  • [Cites] J Neurochem. 1997 Jan;68(1):402-9 [8978752.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Feb;142(2):278-87 [9070350.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4318-23 [9113987.001]
  • [Cites] Neuroscience. 1998 Mar;83(2):393-411 [9460749.001]
  • [Cites] J Neuroimmunol. 1998 Feb;82(1):13-21 [9526841.001]
  • [Cites] FEBS Lett. 1998 Sep 25;436(1):6-10 [9771884.001]
  • [Cites] Mol Pharmacol. 1998 Nov;54(5):834-43 [9804618.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3605-15 [9808554.001]
  • [Cites] Hypertension. 1999 Jan;33(1 Pt 2):429-34 [9931142.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Feb 5;64(2):193-8 [9931487.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Mar;288(3):1357-66 [10027878.001]
  • [Cites] Eur J Neurosci. 1999 Feb;11(2):691-9 [10051770.001]
  • [Cites] Biochem Pharmacol. 1999 Apr 1;57(7):727-41 [10075079.001]
  • [Cites] J Neurochem. 1999 Apr;72(4):1759-68 [10098887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4668-73 [10200320.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Jun;289(3):1620-5 [10336560.001]
  • [Cites] Nature. 1999 Jul 29;400(6743):452-7 [10440374.001]
  • [Cites] Eur J Pharmacol. 1999 Jul 14;377(1):117-25 [10448934.001]
  • [Cites] Glia. 2005 Jan 15;49(2):211-9 [15390091.001]
  • [Cites] Mol Pharmacol. 2005 Jan;67(1):15-9 [15465922.001]
  • [Cites] J Neurochem. 2005 Feb;92(4):895-903 [15686492.001]
  • [Cites] J Neurosci. 2005 Feb 23;25(8):1904-13 [15728830.001]
  • [Cites] J Neurosci. 2005 Mar 9;25(10):2530-6 [15758162.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12212-20 [15657045.001]
  • [Cites] Br J Pharmacol. 2005 Apr;144(8):1032-6 [15700028.001]
  • [Cites] FEBS Lett. 1995 Aug 7;369(2-3):177-82 [7544292.001]
  • [Cites] Mol Pharmacol. 1995 Sep;48(3):443-50 [7565624.001]
  • [Cites] J Neurosci. 1995 Oct;15(10):6552-61 [7472417.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):173-83 [17237277.001]
  • [Cites] J Neurochem. 2007 Apr;101(2):389-96 [17250681.001]
  • [Cites] J Neurosci. 2007 Apr 4;27(14):3663-76 [17409230.001]
  • [Cites] Nat Med. 2007 Apr;13(4):492-7 [17401376.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jun;321(3):930-7 [17379772.001]
  • [Cites] Br J Pharmacol. 2007 Aug;151(8):1343-51 [17592505.001]
  • [Cites] J Neurosci. 2007 Sep 5;27(36):9537-44 [17804615.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 3;362(4):928-34 [17765871.001]
  • [Cites] Br J Pharmacol. 2007 Nov;152(5):825-31 [17704827.001]
  • [Cites] Br J Pharmacol. 2007 Nov;152(5):699-708 [17704831.001]
  • [Cites] Br J Pharmacol. 2007 Nov;152(5):734-43 [17906680.001]
  • [Cites] PLoS Biol. 2007 Oct;5(10):e269 [17927447.001]
  • [Cites] J Neurochem. 2007 Dec;103(5):1907-16 [17868306.001]
  • [Cites] Br J Pharmacol. 2007 Dec;152(7):1092-101 [17876302.001]
  • [Cites] Mol Pharmacol. 2008 Feb;73(2):441-50 [17965195.001]
  • [Cites] PLoS One. 2008;3(2):e1640 [18286196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2699-704 [18263732.001]
  • [Cites] Neuron. 2008 Mar 27;57(6):883-93 [18367089.001]
  • [Cites] J Cell Sci. 2008 May 15;121(Pt 10):1704-17 [18445684.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Jun;325(3):1007-15 [18354058.001]
  • [Cites] Glia. 2009 Feb;57(3):286-94 [18837048.001]
  • [Cites] FASEB J. 2009 Jan;23(1):183-93 [18757503.001]
  • [Cites] Pharmacol Ther. 2009 May;122(2):83-96 [19248809.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3984-9 [8633002.001]
  • [Cites] Eur J Biochem. 1996 May 1;237(3):704-11 [8647116.001]
  • [Cites] J Biol Chem. 1996 Aug 9;271(32):19238-42 [8702604.001]
  • [Cites] Neurosci Lett. 2002 Aug 23;329(1):13-6 [12161251.001]
  • [Cites] Biochem J. 2002 Aug 15;366(Pt 1):137-44 [12010121.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Sep;278(3):989-99 [8819477.001]
  • [Cites] Eur J Biochem. 1995 Aug 15;232(1):54-61 [7556170.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Dec;291(3):1156-63 [10565837.001]
  • [Cites] Mol Pharmacol. 1999 Dec;56(6):1362-9 [10570066.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14136-41 [10570211.001]
  • [Cites] Glia. 2000 Jan 1;29(1):58-69 [10594923.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):605-12 [10617657.001]
  • [Cites] Nat Med. 2000 Mar;6(3):313-9 [10700234.001]
  • [Cites] Eur J Pharmacol. 2000 Apr 21;395(1):1-7 [10781666.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):15621-8 [10821843.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9561-6 [10920191.001]
  • [Cites] J Biol Chem. 2000 Oct 13;275(41):31938-45 [10913156.001]
  • [Cites] Peptides. 2000 Nov;21(11):1735-42 [11090929.001]
  • [Cites] Chem Phys Lipids. 2000 Nov;108(1-2):53-70 [11106782.001]
  • [Cites] J Neurosci. 2001 Feb 1;21(3):823-33 [11157068.001]
  • [Cites] EMBO J. 2001 Jan 15;20(1-2):47-54 [11226154.001]
  • [Cites] Arch Gen Psychiatry. 2001 Apr;58(4):322-8 [11296091.001]
  • [Cites] Mol Pharmacol. 2001 Jul;60(1):155-63 [11408610.001]
  • [Cites] Eur J Pharmacol. 2001 Jul 6;423(2-3):235-41 [11448490.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5784-9 [11479216.001]
  • [Cites] Neuroscience. 2001;106(1):1-4 [11564411.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Dec;299(3):951-9 [11714882.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 11;290(1):91-6 [11779138.001]
  • [Cites] Int Immunopharmacol. 2002 Jan;2(1):69-82 [11789671.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 22;292(1):231-5 [11890697.001]
  • [Cites] J Neurosci Res. 2002 Mar 15;67(6):829-36 [11891798.001]
  • [Cites] Pharmacol Rev. 2002 Jun;54(2):161-202 [12037135.001]
  • [Cites] J Neurosci. 2002 Jun 1;22(11):4720-7 [12040079.001]
  • [Cites] Stroke. 2002 Aug;33(8):2112-4 [12154273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11393-8 [16849427.001]
  • [Cites] J Neurochem. 2006 Aug;98(3):886-93 [16893424.001]
  • [Cites] Cell Mol Life Sci. 2006 Sep;63(17):2057-66 [16909207.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4322-9 [16982866.001]
  • [Cites] J Biol Chem. 2006 Oct 27;281(43):32879-90 [16954222.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1074:514-36 [17105950.001]
  • [Cites] Exp Neurol. 2007 Jan;203(1):246-57 [17010339.001]
  • [Cites] J Neurosci. 2002 Nov 15;22(22):9742-53 [12427829.001]
  • [Cites] Glia. 2003 Jan 15;41(2):161-8 [12509806.001]
  • [Cites] J Neurochem. 2003 Feb;84(3):592-601 [12558979.001]
  • [Cites] J Neurosci. 2003 Feb 15;23(4):1398-405 [12598628.001]
  • [Cites] Mol Pharmacol. 2003 Mar;63(3):699-705 [12606780.001]
  • [Cites] Arch Toxicol. 2003 Apr;77(4):201-7 [12698235.001]
  • [Cites] Br J Pharmacol. 2003 Apr;138(7):1320-32 [12711633.001]
  • [Cites] Br J Pharmacol. 2003 Jun;139(4):775-86 [12813001.001]
  • [Cites] Eur J Neurosci. 2003 Jun;17(12):2750-4 [12823482.001]
  • [Cites] Eur J Pharmacol. 2003 Aug 8;474(2-3):195-8 [12921861.001]
  • [Cites] J Neurosci. 2003 Aug 27;23(21):7767-75 [12944505.001]
  • [Cites] Biochem Pharmacol. 2003 Sep 1;66(5):757-67 [12948856.001]
  • [Cites] Science. 2003 Oct 3;302(5642):84-8 [14526074.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):46188-94 [12952947.001]
  • [Cites] J Neurosci. 2003 Dec 3;23(35):11136-41 [14657172.001]
  • [Cites] Science. 2005 Oct 14;310(5746):329-32 [16224028.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 25;337(3):824-31 [16213464.001]
  • [Cites] Eur J Neurosci. 2005 Nov;22(9):2387-91 [16262678.001]
  • [Cites] Neuron. 2006 Jan 5;49(1):67-79 [16387640.001]
  • [Cites] Trends Pharmacol Sci. 2006 Jan;27(1):1-4 [16318877.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Curr Pharm Des. 2006;12(2):227-39 [16454739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2428-33 [16467152.001]
  • [Cites] Brain Res. 2006 Feb 3;1071(1):10-23 [16472786.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Apr;317(1):428-38 [16352700.001]
  • [Cites] BMC Neurol. 2006;6:12 [16512913.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):301-12 [16616335.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7895-900 [16672367.001]
  • (PMID = 20468046.001).
  • [ISSN] 1098-1136
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA021285-03; United States / NIDA NIH HHS / DA / DA014486-09; United States / NIDA NIH HHS / DA / R01 DA021285; United States / NIDA NIH HHS / DA / R01 DA014486; United States / NIDA NIH HHS / DA / DA 21285; United States / NIDA NIH HHS / DA / DA021285-03; United States / NIDA NIH HHS / DA / DA 14486; United States / NIDA NIH HHS / DA / R01 DA014486-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cannabinoids; 0 / Receptor, Cannabinoid, CB1; 0 / Receptor, Cannabinoid, CB2; 0 / Receptors, Cell Surface
  • [Number-of-references] 161
  • [Other-IDs] NLM/ NIHMS221091; NLM/ PMC2919281
  •  go-up   go-down


84. Kumar DM, Thota B, Shinde SV, Prasanna KV, Hegde AS, Arivazhagan A, Chandramouli BA, Santosh V, Somasundaram K: Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J Proteome Res; 2010 Nov 5;9(11):5557-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth.
  • Glioblastoma (GBM; grade IV astrocytoma) is the most malignant and common primary brain tumor in adults.
  • Using combination of 2-DE and MALDI-TOF MS, we analyzed 14 GBM and 6 normal control sera and identified haptoglobin α2 chain as an up-regulated serum protein in GBM patients.
  • GBM-specific up-regulation was confirmed by ELISA based quantitation of haptoglobin (Hp) in the serum of 99 GBM patients as against lower grades (49 grade III/AA; 26 grade II/DA) and 26 normal individuals (p = 0.0001).
  • Further validation using RT-qPCR on an independent set (n = 78) of tumor and normal brain (n = 4) samples and immunohistochemcial staining on a subset (n = 42) of above samples showed increasing levels of transcript and protein with tumor grade and were highest in GBM (p = <0.0001 and <0.0001, respectively).
  • Further, we demonstrate that both human glioma and mouse melanoma cells overexpressing Hp showed increased tumor growth.
  • Thus, we have identified haptoglobin as a GBM-specific serum marker with a role on glioma tumor growth and migration.
  • [MeSH-minor] Animals. Astrocytes / chemistry. Astrocytes / pathology. Biomarkers, Tumor / blood. Case-Control Studies. Cell Line, Tumor. Cell Movement. Cell Proliferation. Humans. Melanoma / chemistry. Melanoma / pathology. Mice. Up-Regulation

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20822092.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HP protein, human; 0 / Haptoglobins
  •  go-up   go-down


85. Doherty MJ, Hampson NB: Partial seizure provoked by hyperbaric oxygen therapy: possible mechanisms and implications. Epilepsia; 2005 Jun;46(6):974-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a patient after resection of anaplastic astrocytoma and 5,580 cGy of total external-beam radiation treatments with brain radiation necrosis who underwent HBO2 therapy and developed a partial seizure during treatment.
  • [MeSH-minor] Astrocytoma / radiotherapy. Astrocytoma / surgery. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Combined Modality Therapy. Humans. Male. Middle Aged. Necrosis / etiology. Necrosis / pathology. Necrosis / therapy. Radiotherapy, Conformal / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946345.001).
  • [ISSN] 0013-9580
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Shibahara J, Fukayama M: Secondary glioblastoma with advanced neuronal immunophenotype. Virchows Arch; 2005 Sep;447(3):665-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe an unusual progression of astrocytoma into secondary glioblastoma exhibiting advanced neuronal immunophenotype.
  • A tumor of the left frontal lobe of a 35-year-old man was diagnosed as astrocytoma.
  • The tumor was treated by partial removal with postoperative chemoradiotherapy, followed by extensive removal of the residual regrowing tumor 5 month later.
  • A secondary tumor was discovered and partially resected 8 years later, but the patient died 11 months following the operation due to extensive tumor progression showing subarachnoidal and intraventricular dissemination.
  • The secondary tumor was small cell-predominant, highly proliferative tumor with an extremely high MIB-1 labeling index (80%).
  • Unexpectedly, most of the tumor cells were positive for neuronal markers (synaptophysin and NeuN), but not for glial fibrillary acidic protein (GFAP).
  • Retrospective examination of the original tumor revealed not only diffuse GFAP expression, but also neuronal marker expressions in small numbers of tumor cells that were hard to discriminate from the other cells on hematoxylin-eosin (HE) stain.
  • This way of malignant progression of astrocytoma was quite unusual.
  • Although the secondary tumor was classified as glioblastoma according to World Health Organization (WHO) classification (2000), it might be categorized into new variants of malignant glioneuronal tumors proposed recently.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Fatal Outcome. Humans. Immunohistochemistry. Immunophenotyping. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2004 Dec;55(6):1377-91: discussion 1391-2 [15574220.001]
  • [Cites] Clin Neuropathol. 1994 Jan-Feb;13(1):1-11 [7518371.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):523-30 [9815715.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):297-306 [8293189.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Mar;63(3):185-92 [15055442.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] Nat Rev Neurosci. 2001 Apr;2(4):287-93 [11283751.001]
  • [Cites] Am J Pathol. 1991 Jul;139(1):67-79 [1713022.001]
  • (PMID = 15968544.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Liu M, Dai B, Kang SH, Ban K, Huang FJ, Lang FF, Aldape KD, Xie TX, Pelloski CE, Xie K, Sawaya R, Huang S: FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res; 2006 Apr 1;66(7):3593-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcription factor Forkhead box M1 (FoxM1) is overexpressed in malignant glioma.
  • The level of FoxM1 protein expression in human glioma tissues was directly correlated with the glioma grade.
  • Enforced FoxM1B expression caused SW1783 and Hs683 glioma cells, which do not form tumor xenografts, to regain tumorigenicity in nude mouse model systems.
  • Moreover, gliomas that arose from FoxM1B-transfected anaplastic astrocytoma SW1783 cells displayed glioblastoma multiforme phenotypes.
  • Therefore, FoxM1 might be a new potential target of therapy for human malignant gliomas.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Forkhead Transcription Factors / biosynthesis. Glioblastoma / metabolism. Glioblastoma / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cyclin D1 / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Humans. Mice. Mice, Nude. Protein Isoforms. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. S-Phase Kinase-Associated Proteins / metabolism. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585184.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Foxm1 protein, mouse; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / S-Phase Kinase-Associated Proteins; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


88. Hagemann C, Anacker J, Gerngras S, Kühnel S, Said HM, Patel R, Kämmerer U, Vordermark D, Roosen K, Vince GH: Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas. Oncol Rep; 2008 Aug;20(2):301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas.
  • Both proteins are also involved in the regulation of tumor growth.
  • Glioblastomas are the most prevalent malignant brain tumors in adults, characterized by increased invasiveness, an aggressive local growth pattern and short survival periods of patients.
  • In this study, we analysed the expression of microcephalin mRNA and ASPM mRNA and protein in a panel of 15 glioblastomas and 15 astrocytoma WHO grade II by semi-quantitative RT-PCR, Western blotting and immunohistochemistry.
  • Whereas microcephalin expression did not seem to be altered during glioma development, there was a clear increase in ASPM mRNA and protein expression that corresponded with the WHO grade of the tumor.
  • [MeSH-minor] Blotting, Western. Cell Nucleus / metabolism. Genes, Recessive. Humans. Immunoenzyme Techniques. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured


89. Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G: Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. Radiology; 2006 Feb;238(2):658-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response.
  • PURPOSE: To determine retrospectively whether relative cerebral blood volume (CBV) measurements can be used to predict clinical response in patients with low-grade gliomas.
  • Thirty-five patients (23 male and 12 female patients; median age, 39 years; range, 4-80 years) with histologically diagnosed low-grade gliomas (21 low-grade astrocytomas and 14 low-grade oligodendrogliomas and low-grade mixed oligoastrocytomas) were examined with dynamic susceptibility-weighted contrast material-enhanced perfusion magnetic resonance (MR) imaging.
  • Tumor volumes and relative CBV measurements were obtained at initial examination and follow-up.
  • Lesions with low baseline relative CBV had stable tumor volumes at follow-up over time, whereas those with high baseline relative CBV (>1.75) had progressively increasing tumor volumes over time.
  • CONCLUSION: Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging can help to identify low-grade gliomas that will progress rapidly and a subset of low-grade gliomas that have a propensity for malignant transformation.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Magnetic Resonance Imaging. Oligodendroglioma / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2006
  • [CommentIn] Radiology. 2008 Mar;246(3):989 [18309030.001]
  • (PMID = 16396838.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA093992
  • [Publication-type] Duplicate Publication; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


90. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol; 2010 Dec;120(6):707-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
  • WHO grading of human brain tumors extends beyond a strictly histological grading system by providing a basis predictive for the clinical behavior of the respective neoplasm.
  • For example, patients with glioblastoma WHO grade IV usually show a less favorable clinical course and receive more aggressive first-line treatment than patients with anaplastic astrocytoma WHO grade III.
  • Here we provide evidence that the IDH1 status is more prognostic for overall survival than standard histological criteria that differentiate high-grade astrocytomas.
  • We sequenced the isocitrate dehydrogenase 1 gene (IDH1) at codon 132 in 382 patients with anaplastic astrocytoma and glioblastoma from the NOA-04 trial and from a prospective translational cohort study of the German Glioma Network.
  • Patients with anaplastic astrocytomas carried IDH1 mutations in 60%, and patients with glioblastomas in 7.2%.
  • The sequence from more favorable to poorer outcome was (1) anaplastic astrocytoma with IDH1 mutation, (2) glioblastoma with IDH1 mutation, (3) anaplastic astrocytoma without IDH1 mutation and (4) glioblastoma without IDH1 mutation (p < 0.0001).
  • In this combined set of anaplastic astrocytomas and glioblastomas both, IDH1 mutation and IDH1 expression status were of greater prognostic relevance than histological diagnosis according to the current WHO classification system.
  • We propose to complement the current WHO classification and grading of high-grade astrocytic gliomas by the IDH1 mutation status and to use this combined histological and molecular classification in future clinical trials.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / pathology. Cohort Studies. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Young Adult


91. Stupp R, Reni M, Gatta G, Mazza E, Vecht C: Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol; 2007 Jul;63(1):72-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma in adults.
  • Anaplastic astrocytoma is an uncommon disease in the adult population.
  • Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy.
  • In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Clinical Trials, Phase II as Topic. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prognosis. Risk Factors. Survival Analysis


92. Das A, Simmons C, Danielpour M: A congenital brain tumor associated with assisted in vitro fertilization. Case report. J Neurosurg; 2005 Nov;103(5 Suppl):451-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A congenital brain tumor associated with assisted in vitro fertilization. Case report.
  • In this report the authors describe the clinical features of a rare neonatal anaplastic astrocytoma in the setting of in vitro fertilization (IVF).
  • Grosstotal resection of an anaplastic astrocytoma was followed by chemotherapy with temozolomide and vincristine.
  • [MeSH-major] Astrocytoma / congenital. Brain Neoplasms / congenital. Fertilization in Vitro / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2007 May;106(5 Suppl):418; author reply 418-9 [17566216.001]
  • (PMID = 16302619.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


93. Gururangan S, Frankel W, Broaddus R, Clendenning M, Senter L, McDonald M, Eastwood J, Reardon D, Vredenburgh J, Quinn J, Friedman HS: Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro Oncol; 2008 Feb;10(1):93-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.
  • We describe the case of a patient with transcobalamin II deficiency, hypogammaglobulinemia, absent corpus callosum, and mental retardation who presented at an early age with colorectal cancer and multifocal anaplastic astrocytoma.
  • He was found to have a possible germline mutation of the PMS2 gene, as evidenced by absent protein expression in both normal and tumor tissues.
  • [MeSH-major] Abnormalities, Multiple / genetics. Adenosine Triphosphatases / genetics. Astrocytoma / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics


94. Kim JH, Choi C, Benveniste EN, Kwon D: TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells. Biochem Biophys Res Commun; 2008 Dec 5;377(1):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells.
  • Matrix metalloproteinase-9 (MMP-9) is an important angiogenic and prognostic factor in malignant tumors.
  • Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known as the death ligand, which induces preferential apoptosis of transformed tumor cells.
  • We demonstrated that TRAIL induces MMP-9 expression in human astrocytoma cells, which is preceded by activation of extracellular signal-regulated protein kinase (ERK).
  • These findings indicate that TRAIL treatment in human astrocytoma cells leads to the activation of NF-kappaB and subsequent expression of MMP-9, which are dependent on ERK activation.
  • Collectively, these results suggest that TRAIL has alternative biological functions in addition to its role in inducing apoptosis in human malignant astrocytoma cells.
  • [MeSH-major] Astrocytoma / enzymology. Extracellular Signal-Regulated MAP Kinases / metabolism. Matrix Metalloproteinase 9 / biosynthesis. TNF-Related Apoptosis-Inducing Ligand / physiology
  • [MeSH-minor] Butadienes / pharmacology. Cell Line, Tumor. Enzyme Activation. Humans. NF-kappa B / metabolism. Nitriles / pharmacology. Protein Kinase Inhibitors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834856.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Butadienes; 0 / NF-kappa B; 0 / Nitriles; 0 / Protein Kinase Inhibitors; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / U 0126; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


95. Arslantas A, Artan S, Oner U, Müslümanoglu MH, Ozdemir M, Durmaz R, Arslantas D, Vural M, Cosan E, Atasoy MA: Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res; 2007;13(1):39-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas.
  • To extend our understanding of potential stepwise genetic alterations that may underlie tumor progression from low-grade astrocytomas to glioblastomas, histopathologic and comparative genomic hybridization analyses were performed on tumor specimens from 68 primary lesions, including 40 glioblastomas, 10 anaplastic and 18 low-grade astrocytomas.
  • The number of aberrations per case increased towards the higher grade tumors (grade II: 1.66+/-1.49; grade III: 2.80+/-1.68; grade IV: 3.02+/-1.07; F=6.955, p=0.002).
  • A gain of 7/7q was common and the most frequently seen aberration in low-grade astrocytomas, whereas loss of 10q was the most frequently seen anomaly in anaplastic astrocytomas and glioblastomas.
  • Chromosome 10/10q deletion and combination of 1p, 19q and 17p deletions were specific to high-grade astrocytic tumors.
  • The genomic copy deletions of chromosomes 1p and 19q might provide an alternative mechanism in the genesis of astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Chromosome Deletion. Glioblastoma / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurol Belg. 2002 Jun;102(2):53-62 [12161900.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):375-86 [10433931.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1397-401 [8137236.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Jan;43(1):12-8; discussion 19 [12568317.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Apr;61(4):321-8 [11939587.001]
  • [Cites] Mol Carcinog. 2003 Jan;36(1):6-14 [12503074.001]
  • [Cites] Hum Genet. 1993 Sep;92(2):169-74 [8370584.001]
  • [Cites] Front Biosci. 2003 May 01;8:e281-8 [12700122.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):32-9 [9288095.001]
  • [Cites] Anticancer Res. 1994 Mar-Apr;14(2A):577-9 [8017863.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7683-8 [11606412.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jan;42(1):68-77 [15472895.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] Clin Neurol Neurosurg. 1997 May;99(2):117-23 [9213056.001]
  • [Cites] Neurosurg Rev. 2004 Jan;27(1):58-64 [12845540.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1203-18 [8203461.001]
  • [Cites] Oncogene. 1997 Jun 19;14(24):2927-33 [9205099.001]
  • [Cites] Cancer Lett. 1999 Jan 8;135(1):61-6 [10077222.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):424-8 [8595154.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):150-4 [10096247.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1141-50 [12370766.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):124-30 [15970925.001]
  • [Cites] Hum Pathol. 2000 May;31(5):608-14 [10836301.001]
  • [Cites] Virchows Arch. 1995;427(2):113-8 [7582239.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6353-8 [7987828.001]
  • (PMID = 17387387.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


96. Ferroir JP, Marro B, Belkacemi Y, Stilhart B, Schlienger M: [Cerebral infarction related to intracranial radiation arteritis twenty-four years after encephalic radiation therapy]. Rev Neurol (Paris); 2007 Jan;163(1):96-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a resolutive late cerebral ischemic event, related to radiation induced vasculopathy of the left posterior cerebral artery, documented by MRI, situated in the irradiated volume 24 years before, for an astrocytome with malignant potential.
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Humans. Male. Radiotherapy / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304179.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


97. Pavon LF, Marti LC, Sibov TT, Malheiros SM, Oliveira DM, Guilhen DD, Camargo-Mathias MI, Amaro Junior E, Gamarra LF: The ultrastructural study of tumorigenic cells using nanobiomarkers. Cancer Biother Radiopharm; 2010 Jun;25(3):289-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite recent advances, patients with malignant brain tumors still have a poor prognosis.
  • Glioblastoma (WHO grade 4 astrocytoma), the most malignant brain tumor, represents 50% of all astrocytomas, with a median survival rate of <1 year.
  • The process of tumor cell labeling using nanoparticles can successfully contribute to the identification of tumorigenic cells and consequently for better understanding of glioblastoma genesis and recurrence.
  • In addition, this method may help further studies in tumor imaging, diagnosis, and prognostic markers detection.
  • [MeSH-minor] Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / metabolism. Antigens, CD / immunology. Antigens, CD / metabolism. Antigens, CD29 / immunology. Antigens, CD29 / metabolism. Antigens, CD44 / immunology. Antigens, CD44 / metabolism. Biomarkers / analysis. Biomarkers / chemistry. Cell Line, Tumor. Cell Membrane / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. Cytoplasmic Vesicles / metabolism. Endocytosis / immunology. Flow Cytometry. Forkhead Transcription Factors / chemistry. Forkhead Transcription Factors / metabolism. Glycoproteins / immunology. Glycoproteins / metabolism. Humans. Immunophenotyping. Magnetite Nanoparticles / chemistry. Microscopy, Electron, Transmission. Nanomedicine / methods. Peptides / immunology. Peptides / metabolism. Quantum Dots. Receptors, Cell Surface / immunology. Receptors, Cell Surface / metabolism. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578834.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD29; 0 / Antigens, CD44; 0 / Biomarkers; 0 / CD44 protein, human; 0 / ENG protein, human; 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors; 0 / Glycoproteins; 0 / Magnetite Nanoparticles; 0 / Peptides; 0 / Receptors, Cell Surface
  •  go-up   go-down


98. Shirahata M, Oba S, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Ishii S, Takahashi JA, Kato K: Using gene expression profiling to identify a prognostic molecular spectrum in gliomas. Cancer Sci; 2009 Jan;100(1):165-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression levels of these genes in 152 gliomas (100 glioblastomas, 21 anaplastic astrocytomas, 19 diffuse astrocytomas, and 12 anaplastic oligodendrogliomas) were measured using adapter-tagged competitive polymerase chain reaction, a high-throughput reverse transcription-polymerase chain reaction technique.
  • The g